1. Russian National Research Medical University N. I. Pirogov, Ministry of Health of Russia, Moscow, Russia

Keywords: gastroenterology, intrascopy, diagnostiс, children

Abstract: The article continues the tradition of writing scientific reviews concerning achievements in the field of pediatric gastroenterology, laid down by the leaders of Russian pediatrics and neonatology — A. V. Mazurin, N. G. Zernov, B. G. Apostolov, A. A. Baranov, V. F. Uchaykin, G. V. Rimarchuk, Yu. G. Mukhina, P. L. Shcherbakov, S. V. Belmer, I. Yu. Melnikova and others. The article discusses the origins, development and successes of modern Russian pediatric gastroenterology. Important in the diagnosis of diseases of the digestive system in children, beginning at an early age (up to 3 years), along with laboratory methods, have played methods of medical intrascopy. The main achievements in the study of diseases of the esophagus, stomach, intestines, hepatobiliary system, pancreas are analyzed. Prospects for the development of pediatric gastroenterology as an independent area of pediatrics are being advanced.

• References total 38 ⇓ :: .
  1. Zaprudnov A. M., Grigoriev K. I., Haritonova L. A., Bogomaz L. V., Yudina T. M. Problems and perspectives of modern pediatric gastroenterology. Pediatria (Rus.). 2016; 95 (6): 10–18.
  2. Lazebnik L. B., Konev Yu. V. Historical features and semantic difficulties of using the terms denoting multiplicity of diseases in one patient. Experimental and Clinical Gastroenterology. 2018;154(6): 4–9.
  3. Khavkin A. I., Gurova MM, Novikova V. P. The use of the comorbidity index to assess the effect of comorbidity on the course of chronic gastroduodenitis in adolescents. Pediatrics (Rus.). 2018; 97 (6): 19–25.
  4. Tsukanov A. S., Shubin V. P., Kuzminov A. M., et al. Differential Diagnosis of MutYH-Associated Polyposis from Sporadic Colon Polyps. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018; 28(6): 51–57. https://doi.org/10.22416/1382–4376–2018–28–6–51–57
  5. Ivanov D. O., Novikova V. P. Congenital malabsorption of glucose and galactose in newborns. Vopr. of children’s nutrition. 2018; 16(3): 38–42.
  6. Demikova NS, Podolnaya MA, Lapina AS, Asanov A. Yu. Clinical diversity and nosological structure of atresia of the anorectal department. Pediatrics (Rus.). 2018; 97(6): 63–69.
  7. Kozlov Yu.A., Smirnov A. A., Novozhilov V. A., Rasputin A. A., et al. Oral endoscopic gastric myotomy (G-POEM) in a patient with congenital hypertrophic pyloric stenosis is the first clinical experience. Pediatrics (Rus.). 2018; 97(5): 8–13.
  8. Ivanova I. I., Gnusaev S. F., Sukhorukov V. S. Experience with L-carnitine in children with chronic gastroduodenitis and connective tissue dysplasia. Vopr of practical pediatrics. 2018; 13 (6): 72–78.
  9. Ivashkin V. T., Maev I. V., Trukhmanov A. S., Lapina T. L. et al. Clinical Guidelines of the Russian Gastroenterological Association on the Diagnostics and Treatment of Eosinophilic Esophagitis. Russian Journal of Gastroentorology, Hepatology, Coloproctology. 2018; 28(6):84–98. https://doi.org/10.22416/1382–4376–2018–28–6–84–98
  10. Erdes S. I., Antishin A. S., Aldakovsky V. I., Polotnyanko E. Yu., Borisova E. V. Eosinophilic esophagitis in children. Pediatrics (Rus.). 2018; 97(6): 113–123.
  11. Aminova A. I., Akatova A. A., Gumbatova Z. F., Vozgoment O. V., Abdullaeva G. D. Clinical and pathogenetic rationale for serological methods for the diagnosis of Helicobacter pylori in children. Vopr of practical pediatrics. 2018; 13(6): 40–49. DOI: 10.20953 / 1817–7646–2018–6–40–49
  12. Zimmerman Ya. S. Persistent errors of modern gastroenterology. Clin pharmacol. ter. 2016(5): 5–12.
  13. Novikova V. P., Krulevsky V. A., Petrovsky A. N. Epstein-Barr virus infection with non-Helicobacter chronic gastritis in people of different ages. Preventive and clinical medicine. 2008 (3): 87–90.
  14. Smyk DS, Koutsoumpas AL, Mytilinaiou MG, Rigopoulou EI, Sakkas LI, Bogdanos DP. Helicobacter pylori and autoimmune disease: cause or bystander. World J Gastroenterol. 2014; 20: 613–629.
  15. Celiac disease in children. Ed. S. V. Belmer and M. O. Revnovа. 2nd ed. Moscow, MEDPRAKTIKA-M, 2013: 416 p.
  16. Gurova M.M, Novikova V. P. Evolutionary aspects of neonatal gastroenterology: the formation of the intestinal microbiome and the importance of the nutritional factor in the first months of life. Vopr of children’s nutrition. 2018; 16(1): 34–41.
  17. Kharitonova L. A., Grigoriev K. I., Borzakova S. N. Human microbiote: how a new scientifi c paradigm changes medical practice. Experimental and Clinical Gastroenterology. 2019;161(1): 55–63. DOI: 10.31146/1682–8658-ecg-161–1–55–63
  18. Davydovskaya A. A., Gordeeva E. A., Pyryeva E. A. et al. Infant Colic: Is Everything So Obvious? Pediatrics (Russ.). 2019; 98(2): 192–197.
  19. Grigoriev K. I. Infant intestinal colic syndrome: diagnosis, treatment, care. Nurse (Rus.). 2011; 8: 15–20.
  20. Pimenova E. S., Morozov D. A., Fomenko O. Yu., Guseva N. B., Yakovenko D. D. Diagnosis of dissynergic defecation in children using anorectal manometry. Pediatrics (Russ.). 2017; 96(6): 14–18.
  21. Tsvetkova L. N., Mukhina T. F., Tsvetkov P. M., Goryacheva O. A. Mechanism of formation and peculiarities of chronic constipation in children. Pediatrics (Russ.). 2017; 96 (6): 8–13.
  22. Chubarova A. I., Erpuleva Yu. V. Modern management of children with short bowel syndrome and other forms of chronic intestinal failure. M.: GEOTAR-Media, 2016: 88 p.
  23. Sukhotnik I. G. Short bowel syndrome in children. Russian Bulletin of Pediatric Surgery, Anesthesiology and Resuscitation. 2017. 7(3): 98–115.
  24. Schigoleva A. E., Shumilov P. V., Shumilov A. P. Inflammatory bowel disease with very early onset. Pediatrics (Russ.). 2018; 97(6): 141–146.
  25. Khalif I. L., Shapina M. V., Orlova L. P., Evgrafov Р. G. Ulcerative colitis treatment efficiency assessed by ultrasonography with contrast enhancement. Experimental and Clinical Gastroenterology. 2018;153(5): 32–37.
  26. Fedulova E. N., Shumilova O. V., Tutina O. A., Medyantseva G. V. The prognostic algorithm of the adverse course of Crohn’s disease in pediatric practice. Pediatrics (Russ.). 2017; 96(6): 19–24.
  27. Cani P. D. Human gut microbiome: hopes, threats and promises. Gut. 2018; 1–10. Doi:10.1136/gutjnl-2018–316723
  28. Shenderov B. A., Yudin S. M., Zagaynova A. V., Shevyreva M. P. The role of commensal gut bacteria in the aetiopathogenesis of inflammatory bowel disease: Akkermansia muciniphila. Experimental and Clinical Gastroenterology. 2018;159(11): 4–13. DOI: 10.31146/1682–8658-ecg-159–11–4–13
  29. Shen ZH, Zhu CX, Quan YS, Yang ZY, Wu S, Luo WW, et al. Relationship between intestinal microbiota and ulcerative colitis: Mechanisms and clinical application of probiotics and fecal microbiota transplantation. World J Gastroenterol 2018; 24(1): 5–14
  30. Strokova T. V., Surkov A. G., Bagaeva M. E. et al. Options for the manifestation of autoimmune hepatitis in children. Pediatrics (Russ.). 2018; 97(6): 8–13.
  31. Vlasov N. N., Kornienko E. A., Melnik S. I. Liver disease in children caused by α1-antitrypsin deficiency. Experimental and clinical gastroenterology. 2018; 150(2): 89–99.
  32. Kucheryavy Yu.A., Petrova N. V., Tibilova Z. F. Mutations of a pancreatic secretory trypsin inhibitor gene N34S in idiopathic chronic pancreatitis. Eksp klin gastroenterol. 2011(7):7–12.
  33. Netrebenko O. K. Nutrition in infancy: the road to a long life or to an early painful old age? Pediatrics (Russ.). 2017; 96(1): 67–74.
  34. Borovik T. E., Skvortsova V. A., Lukoyanova O. L. et al. The consensus on infant feeding in the first year of life, which was included in the updated version of the National Program for the Optimization of Feeding Children in the First Year of Life in the Russian Federation (2019). Pediatrics. 2019; 98(1): 210–216.
  35. Kuchma V. R., Gorelova Z. Yu., Ivanenko A. V., Petrenko A. O., Soloveva Yu.V., Flying TA, Uglov S. Yu. Scientific substantiation and development of modern rations for schoolchildren. Pediatrics (Russ.). 2019; 98(3): 124–134.
  36. Zakharova I. N., Lavrova T. E., Talyzina M. F. The road to perfection of breast milk: the “lipid” route of innovation in baby food. Vopr of children’s nutrition. 2018; 16(6): 23–30.
  37. Nikolaeva S. V., Gorelov A. V. Clinical features of acute intestinal infections of combined etiology in children. Pediatrics (Russ.). 2019; 98(1): 174–177.
  38. Zaprudnov AM et al. Clostridium diffcile – infection. In: Bowel diseases in childhood. Moscow, GEOTAR-Media, 2018: 51–59.
      
      

Full text is published :
Kharitonovа L. A., Grigoriev K. I., Zaprudnov A. M. From an idea to realities: modern successes of children’s gastroenterology. Experimental and Clinical Gastroenterology. 2019;171(11): 4–15. (In Russ.) DOI: 10.31146/1682-8658-ecg-171-11-4-15
Read & Download full text

1. Kazan State Medical University, Kazan, Russia
2. Russian National Research Medical University N. I. Pirogov, Ministry of Health of Russia, Moscow, Russia

Keywords: Constipation, children, dietary fi ber, probiotics, laxatives, polyethylene glycol macrogol, lactulose

Abstract: Constipation among children is an extremely widespread state. They arise at any age and may pose major challenges, disrupting the child’s health with the risk of complications, regressing the quality of life of both the child and his family members. Having arisen once, constipation among children can recur, require repeated and prolonged treatment. For children, functional constipation is the most common. According to international recommendations, it is not necessary to resort to complicated methods for its diagnosis, wherein the treatment and prevention of constipation in children requires a fairly strict adherence to diet, motor activity and drug therapy. The evidence base on the use of certain foods for constipation is expanding. The relationship between constipation and intestinal microbiota disturbance was revealed, providing a theoretical basis for the microbial treatment of chronic constipation. Among the wide variety of laxatives traditionally prescribed for constipation in children’s practice, safe and effective use is proven with the use of polyethylene glycol (macrogol) and lactulose.

• References total 25 ⇓ :: .
  1. Lewis M. L. et al. Prevalence of functional gastrointestinal disorders in children and adolescents. The Journal of pediatrics. - 2016, Vol. 177, pp.39-43. e3.
  2. Robin S. G. et al. Prevalence of pediatric functional gastrointestinal disorders utilizing the Rome IV criteria. The Journal of pediatrics. - 2018, Vol. 195, pp.134-139.
  3. Beaudry-Bellefeuille I., Booth D., Lane S. J. Defecation-specific behavior in children with functional defecation issues: A systematic review. The Permanente Journal. - 2017, Vol. 21, pp.17-47
  4. Dubrovskaya M. I. Current Data on Digestive Functional Disorders in Infants. Voprosy sovremennoi pediatrii - Current Pediatrics. - 2013. - Vol. 12, no.4. - Pp. 26-31.
  5. Mugie S., Benninga M. A., Di Lorenzo C. Epidemiology of constipation in children and adults: a systematic review. Best practice & research Clinical gastroenterology. - 2011, Vol. 25, no.1, pp.3-18.
  6. Huang R., Ho S. Y., Lo W. S., Lam T. H. Physical activity and constipation in Hong Kong adolescents. Plos one. - 2014, Vol. 9, no.2, pp.e90193.
  7. Okuda M., Kunitsugu I., Yoshitake N., Sasaki S. The relationship between functional constipation and dietary habits in school-age Japanese children. Journal of nutritional science and vitaminology. - 2019, Vol. 65, no.1, pp.38-44.
  8. Vandenplas Y. et al. Functional gastro-intestinal disorder algorithms focus on early recognition, parental reassurance and nutritional strategies. Acta Paediatrica. - 2016, Vol. 105, no.3, pp.244-252.
  9. Uc A., Hyman P. E., Walker L. S. Functional gastrointestinal disorders in African American children in primary care. Journal of pediatric gastroenterology and nutrition. - 2006, Vol. 42, no.3, pp.270-274.
  10. Levy E. I., Lemmens R., Vandenplas Y., Devreker T. Functional constipation in children: challenges and solutions. Pediatric health, medicine and therapeutics. - 2017, Vol. 8, pp.19-27.
  11. Dumova N. B., Kruchina M. K. Functional constipation in children of different age groups. RMJ. - 2012. - Vol. 20, no.15. - Pp. 792-799.
  12. Tabbers M. M. et al. Evaluation and treatment of functional constipation in infants and children: evidence-based recommendations from ESPGHAN and NASPGHAN. Journal of pediatric gastroenterology and nutrition. - 2014, Vol. 58, no.2, pp.258-274.
  13. Tsvetkova L. N., Mukhina Yu. F., Tsvetkov P. M., Goryacheva O. A. Тhe mechanism of formation and features of the course of chronic constipation in children. Pediatriajournal. - 2017. - Vol. 96, no. 6. - P. 8-13.
  14. Elshimy N. et al. Outcome in children under 5 years of age with constipation: a prospective follow-up study. International journal of clinical practice. - 2000. Vol. 54, no.1, pp.25-27.
  15. Colombo J.M., Wassom M. C., Rosen J. M. Constipation and Encopresis in Childhood. Pediatr Rev. - 2015. Vol.36. - № 9. - С. 392-401.
  16. Blackmer A. B., Farrington E. A. Constipation in the pediatric patient: an overview and pharmacologic considerations. Journal of Pediatric Health Care. - 2010. Vol. 24, no.6, pp.385-399.
  17. Loening-Baucke V. Factors determining outcome in children with chronic constipation and faecal soiling. Gut. - 1989. Vol. 30, no.7, pp.999-1006.
  18. Loening-Baucke V., Cruikshank B., Savage C. Defecation dynamics and behavior profiles in encopretic children. Pediatrics. - 1987, Vol. 80, no.5, pp.672-679.
  19. Liu L. W. C. Chronic constipation: current treatment options. Canadian Journal of Gastroenterology and Hepatology. - 2011, Vol. 25, no.Suppl B, pp.22B-28B.
  20. Cancer [Electronic resource] World Health Organization, 2019. URL: https://www.who.int/ru/news-room/fact-sheets/detail/cancer (Date of access: 05.08.2019)
  21. Hyams J. S. et al. Childhood functional gastrointestinal disorders: child/adolescent. Gastroenterology. - 2016, Vol. 150, no.6, pp.1456-1468. e2.
  22. Mugie S. M., Di Lorenzo C., Benninga M. A. Constipation in childhood. Nature reviews Gastroenterology & hepatology. - 2011, Vol. 8, no.9, pp.502-511.
  23. Sadjadei N. et al. Anti-TTG among children with chronic functional constipation unresponsive to 6 weeks of treatment of constipation. Arquivos de gastroenterologia. - 2017, Vol. 54, no.3, pp.197-200.
  24. Allen P., Lawrence V. N. Pediatric Functional Constipation. StatPearls [Internet]. - StatPearls Publishing, 2019.
  25. Marx M. et al. Functional gastrointestinal disorders: update on the Rome IV criteria. Revue medicale suisse. - 2018, Vol. 14, no.616, pp.1512-1516.
  26. Zeevenhooven J., Koppen I. J. N., Benninga M. A. The new Rome IV criteria for functional gastrointestinal disorders in infants and toddlers. Pediatric gastroenterology, hepatology & nutrition. - 2017, Vol. 20, no.1, pp.1-13.
  27. Khavkin A. I. et al. Functional digestive disturbances in infants: working protocol of diagnostic and treatment. Experimental & clinical gastroenterology. 2014; 101 (1):80-94.
  28. Inan M. et al. Factors associated with childhood constipation. Journal of paediatrics and child health. - 2007, Vol. 43, no.10, pp.700-706.
  29. Jennings A., Davies G. J., Costarelli V., Dettmar P. W. Dietary fibre, fluids and physical activity in relation to constipation symptoms in pre-adolescent children. Journal of child health care. - 2009, Vol. 13, no.2, pp.116-127.
  30. Asakura K., Masayasu S., Sasaki S. Dietary intake, physical activity, and time management are associated with constipation in preschool children in Japan. Asia Pacific journal of clinical nutrition. - 2017, Vol. 26, no.1, pp.118-129.
  31. Portalatin M., Winstead N. Medical management of constipation. Clinics in colon and rectal surgery. - 2012, Vol. 25, no.01, pp.12-19.
  32. Chan M. F. et al. Usual physical activity and endogenous sex hormones in postmenopausal women: the European Prospective Investigation into Cancer-Norfolk Population Study. Cancer Epidemiology and Prevention Biomarkers. - 2007, Vol. 16, no.5, pp.900-905.
  33. Driessen L. M. et al. Preschool physical activity and functional constipation: the Generation R study. Journal of pediatric gastroenterology and nutrition. - 2013, Vol. 57, no.6, pp.768-774.
  34. Boilesen S. N. et al. Water and fluid intake in the prevention and treatment of functional constipation in children and adolescents: is there evidence?. Jornal de Pediatria (Versão em Português). - 2017, Vol. 93, no.4, pp.320-327.
  35. Zakharova I. N., Andryukhina E. N. Modern approaches to treatment of constipation in young children. Med-sovet. - 2011, no.9-10. - Pp. 122-129.
  36. Wald A. et al. A multinational survey of prevalence and patterns of laxative use among adults with self-defined constipation. Alimentary pharmacology & therapeutics. - 2008, Vol. 28, no.7, pp.917-930.
  37. Williams C. L., Bollella M., Wynder E. L. A new recommendation for dietary fiber in childhood. Pediatrics. - 1995, Vol. 96, no.5, pp.985-988.
  38. de Morais M. B., Maffei H. V. L. Constipação intestinal. J Pediatr. - 2000, Vol. 76, no.2, pp.147-156.
  39. Lee W. T. K. et al. Increased prevalence of constipation in pre-school children is attributable to under-consumption of plant foods: A community-based study. Journal of paediatrics and child health. - 2008, Vol. 44, no.4, pp.170-175.
  40. Chan J. S. H. A community-based study of the prevalence of constipation in young children and the role of dietary fibre. Hong Kong Med J. - 2005, Vol. 11, no.6, pp.431-436.
  41. Ternent C. A. et al. Practice parameters for the evaluation and management of constipation. Diseases of the Colon & Rectum. - 2007, Vol. 50, no.12, pp.2013-2022.
  42. Schiller L. R. Review article: the therapy of constipation// Alimentary Pharmacology and Therapeutics. - 2001, Vol. 15, no.6, pp.749-763.
  43. Dreher M. Whole fruits and fruit fiber emerging health effects. Nutrients. - 2018, Vol. 10, no.12, pp.1833.
  44. Slavin J. L., Lloyd B. Health benefits of fruits and vegetables. Advances in nutrition. - 2012, Vol. 3, no.4, pp.506-516.
  45. Veronese N. et al. Dietary fiber and health outcomes: an umbrella review of systematic reviews and meta-analyses. The American journal of clinical nutrition. - 2018, Vol. 107, no.3, pp.436-444.
  46. Miller V. et al. Fruit, vegetable, and legume intake, and cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study. The Lancet. - 2017, Vol. 390, no.10107, pp.2037-2049.
  47. Dreher M. L. Connection between fiber, colonic microbiota, and health across the human life cycle. Dietary Fiber in Health and Disease. - Humana Press, Cham, 2018, pp.67-93.
  48. Suares N. C., Ford A. C. Systematic review: the effects of fibre in the management of chronic idiopathic constipation. Alimentary pharmacology & therapeutics. - 2011, Vol. 33, no.8, pp.895-901.
  49. Bijkerk C. J. et al. Systematic review: the role of different types of fibre in the treatment of irritable bowel syndrome. Alimentary pharmacology & therapeutics. - 2004, Vol. 19, no.3, pp.245-251.
  50. Padayachee A., Day L., Howell K., Gidley M. J. Complexity and health functionality of plant cell wall fibers from fruits and vegetables. Critical reviews in food science and nutrition. - 2017, Vol. 57, no.1, pp.59-81.
  51. Xu L., Yu W., Jiang J., Li N. Clinical benefits after soluble dietary fiber supplementation: a randomized clinical trial in adults with slow-transit constipation. Zhonghua yi xue za zhi. - 2014, Vol. 94, no.48, pp.3813-3816.
  52. Kelsay J. L., Behall K. M., Prather E. S. Effect of fiber from fruits and vegetables on metabolic responses of human subjects I. Bowel transit time, number of defecations, fecal weight, urinary excretions of energy and nitrogen and apparent digestibilities of energy, nitrogen, and fat. The American journal of clinical nutrition. - 1978, Vol. 31, no.7, pp.1149-1153.
  53. Venancio V. P. et al. Polyphenol-rich Mango (Mangifera indica L.) Ameliorate Functional Constipation Symptoms in Humans beyond Equivalent Amount of Fiber. Molecular nutrition & food research. - 2018, Vol. 62, no.12, pp.1701034.
  54. Lever E. et al. Systematic review: the effect of prunes on gastrointestinal function. Alimentary pharmacology & therapeutics. - 2014, Vol. 40, no.7, pp.750-758.
  55. Attaluri A. et al. Randomised clinical trial: dried plums (prunes) vs. psyllium for constipation. Alimentary pharmacology & therapeutics. - 2011, Vol. 33, no.7, pp.822-828.
  56. Rush E. C., Patel M., Plank L. D., Ferguson L. R. Kiwifruit promotes laxation in the elderly. Asia Pacific Journal of Clinical Nutrition. - 2002, Vol. 11, no.2, pp.164-168.
  57. Chan A. O. O., Leung G., Tong T., Wong N. Y. Increasing dietary fiber intake in terms of kiwifruit improves constipation in Chinese patients. World journal of gastroenterology: WJG. - 2007, Vol. 13, no.35, pp.4771-4775.
  58. Cozma-Petruţ A., Loghin F., Miere D., Dumitraşcu D. L. Diet in irritable bowel syndrome: What to recommend, not what to forbid to patients!. World journal of gastroenterology. - 2017, Vol. 23, no.21, pp.3771-3783.
  59. Tabbers M. M., Benninga M. A. Constipation in children: fibre and probiotics. BMJ clinical evidence. - 2015, Vol. 2015.
  60. Axelrod C., Saps M. The role of fiber in the treatment of functional gastrointestinal disorders in children. Nutrients. - 2018, Vol. 10, no.11. - e.1650.
  61. Huang L., Zhu Q., Qu X., Qin H. Microbial treatment in chronic constipation. Science China Life Sciences. - 2018, Vol. 61, no.7, pp.744-752.
  62. Zhao Y., Yu Y. B. Intestinal microbiota and chronic constipation. Springerplus. - 2016, Vol. 5, no.1, pp.1130.
  63. Zhu L. et al. Structural changes in the gut microbiome of constipated patients. Physiological genomics. - 2014, Vol. 46, no.18, pp.679-686.
  64. de Meij T. G. J. et al. Characterization of microbiota in children with chronic functional constipation. PLoS One. - 2016, Vol. 11, no.10, pp.e0164731.
  65. Wojtyniak K., Szajewska H. Systematic review: probiotics for functional constipation in children. European journal of pediatrics. - 2017, Vol. 176, no.9, pp.1155-1162.
  66. Coccorullo P. et al. Lactobacillus reuteri (DSM 17938) in infants with functional chronic constipation: a double-blind, randomized, placebo-controlled study. The Journal of pediatrics. - 2010, Vol. 157, no.4, pp.598-602.
  67. Guerra P. V. P. et al. Pediatric functional constipation treatment with Bifidobacterium-containing yogurt: a crossover, double-blind, controlled trial. World journal of gastroenterology: WJG. - 2011, Vol. 17, no.34, pp.3916-3921.
  68. Banaszkiewicz A., Szajewska H. Ineffectiveness of Lactobacillus GG as an adjunct to lactulose for the treatment of constipation in children: a double-blind, placebo-controlled randomized trial. The Journal of pediatrics. - 2005, Vol. 146, no.3, pp.364-369.
  69. Tabbers M. M. et al. Fermented milk containing Bifidobacterium lactis DN-173 010 in childhood constipation: a randomized, double-blind, controlled trial. Pediatrics. - 2011, Vol. 127, no.6, pp.e1392-e1399.
  70. Sadeghzadeh M. et al. The effect of probiotics on childhood constipation: a randomized controlled double blind clinical trial. International journal of pediatrics. - 2014, Vol. 2014 - e.937212.
  71. Bu L. N. et al. Lactobacillus casei rhamnosus Lcr35 in children with chronic constipation. Pediatrics International. - 2007, Vol. 49, no.4, pp.485-490.
  72. Wojtyniak K., Horvath A., Dziechciarz P., Szajewska H. Lactobacillus casei rhamnosus Lcr35 in the management of functional constipation in children: a randomized trial. The Journal of pediatrics. - 2017, Vol. 184, pp.101-105. e1.
  73. Ge X. et al. Fecal microbiota transplantation in combination with soluble dietary fiber for treatment of slow transit constipation: a pilot study. Archives of medical research. - 2016, Vol. 47, no.3, pp.236-242.
  74. Zhang X. et al. Long-term follow-up of the effects of fecal microbiota transplantation in combination with soluble dietary fiber as a therapeutic regimen in slow transit constipation. Science China Life Sciences. - 2018, Vol. 61, no.7, pp.779-786.
  75. Pasechnikov V. D. Functional constipation caused by delayed transit of intestinal contents. Pharmateca. - 2003, no.10. - С. 16-23.
  76. Maev I. V. et al. Chronic constipation, approaches to diagnosis and treatment. Pharmateca. - 2011, no.12. - Pp. 74-79.
  77. Agafonova N. A., Yakovenko E. P. Chronic constipation Syndrome in patients abusing laxatives of irritating action. RMJ. - 2010. - Vol. 18, no.28. - Pp. 1735-1741.
  78. Müller-Lissner S. et al. Bisacodyl and sodium picosulfate improve bowel function and quality of life in patients with chronic constipation - analysis of pooled data from two randomized controlled trials. Open Journal of Gastroenterology. - 2017, Vol. 7, no.01, pp.32-43.
  79. Johanson J. F., Kralstein J. Chronic constipation: a survey of the patient perspective. Alimentary pharmacology & therapeutics. - 2007, Vol. 25, no.5, pp.599-608.
  80. An evidence-based approach to the management of chronic constipation in North America. American College of Gastroenterology Chronic Constipation. American Journal of Gastroenterology. - 2005, Vol. 100. - S1- S4.
  81. Potapov A. S., Polyakova S. I. The possibility of using lactulose in the treatment of chronic constipation in children. Voprosy sovremennoi pediatrii - Current Pediatrics. - 2003. - Vol. 2, no.2. - Pp. 65-70.
  82. Tsvetkova L. N. Lactulose efficiency in correction constipation in children. Child and adolescent rehabilitation. - 2011. - Vol. 2, no.17. - Pp. 71-77.
  83. Cash B.D., Lacy B. E. The interventions included in the review were: lactulose compared with constipation. Gastroenterology and Hepatology. - 2006, Vol. 2, no.10, pp.736-749.
  84. Kokke F. T. M. et al. A dietary fiber mixture versus lactulose in the treatment of childhood constipation: a double-blind randomized controlled trial. Journal of pediatric gastroenterology and nutrition. - 2008, Vol. 47, no.5, pp.592-597.
  85. DiPalma J. A., vB Cleveland M., McGowan J., Herrera J. L. A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation. The American journal of gastroenterology. - 2007, Vol. 102, no.7, pp.1436-1441.
  86. Candy D., Belsey J. Macrogol (polyethylene glycol) laxatives in children with functional constipation and faecal impaction: a systematic review. Archives of disease in childhood. - 2009, Vol. 94, no.2, pp.156-160.
  87. Chen S. L. et al. Efficacy and complications of polyethylene glycols for treatment of constipation in children: a meta-analysis. Medicine. - 2014, Vol. 93, no.16 - e.65.
  88. Mínguez M., Lopez-Higueras A., Júdez J. Use of polyethylene glycol in functional constipation and fecal impaction. Rev. Esp. Enferm. Dig. - 2016, Vol. 108, pp.790-806.
  89. Gordon M. et al. Osmotic and stimulant laxatives for the management of childhood constipation. Cochrane Database Syst Rev. 2016. Vol.17. - № 8. - CD009118.
  90. Cao Y., Liu S. Lactulose for the treatment of Chinese children with chronic constipation: A randomized controlled trial. Medicine. - 2018, Vol. 97, no.52. - e13794.
  91. Shatnawi M. S. et al. Lactulose versus polyethylene glycol for disimpaction therapy in constipated children, a randomized controlled study. Sudanese journal of paediatrics. - 2019, Vol. 19, no.1, pp.31-36.

Full text is published :
R. A. Fayzullina1, S. V. Belmer Chronic constipation in pediatric practice: what do we know? Anything new? Experimental and Clinical Gastroenterology. 2019;171(11): 16–26. (In Russ.) DOI: 10.31146/1682-8658-ecg-171-11-16-26
Read & Download full text

1. Yaroslavl state medical University, Yaroslavl, 150000, Russia
2. Research and production company “DNA technology”, Moscow, 117587, Russia

Keywords: chronic gastritis, Helicobacter pylori, adolescents

Abstract: The aim of the work. To establish the features of clinical manifestations and pathomorphology of gastric mucosa in Hp - associated chronic gastritis in adolescents, depending on the genetic characteristics of Hp. Patients and methods. In 133 adolescents with Hp-associated gastritis, polymerase chain reaction was used to determine the presence of pathogenicity factors in the HP genome.
Results. In 60,9% of cases, highly pathogenic strains of Helicobacter pylori containing genes Cag (A, C, E, F, H, M, T), UreB, UreI, VacAs1, IceA, BabA, hpaA, AlpB and OipA are detected.
Conclusion. The presence of highly pathogenic strains of Hp does not affect the clinical manifestations of gastritis, but is associated with high rates of contamination, increased inflammation, the appearance of signs of atrophy of the gastric mucosa.

• References total 9 ⇓ :: .
  1. Levit R. M., Spivak E. M., Nadezhin A. S., Akkuratova I. S. On the issue of atrophic gastritis in childhood. Vopr. det. dietol. (Pediatric Nutrition). 2013; 11(2): 63-65. (In Russian).
  2. Nizhevich A. A., Valeeva D. S. Infektsiya Helicobacter pylori v detskom vozraste: sovremennyye aspekty diagnostiki i lecheniya. Bolezni zheludka i dvenadtsatiperstnoy kishki u detey. [Helicobacter pylori infection in childhood: current aspects of diagnosis and treatment. Diseases of the stomach and duodenum in children]. Moscow, MEDPRAKTIKA-M, 2017, pp. 219-201.
  3. Pozdeev О. К., Pozdeeva А. О., Valeeva Y. V., Gulyaev P. E. Mechanisms of interraction of helicobacter pylori with epithelium of gastric mucosa. I. Pathogenic factors promoting successful colonization. Russian Journal of Infection and Immunity. 2018;8(3):273-283. (In Russ.) https://doi.org/10.15789/2220-7619-2018-3-273-283
  4. Sapozhnikov V. G., Vorobiyova A. V. The clinical manifestations of chronic diseases of the digestive system in children. Journal of New Medical Technologies. 2015;22(1):23-26. DOI:10.12737/9071
  5. Filimonov R. M. Teenage Gastroenterology. Moscow, 2008. 576 p.
  6. Abdullah S.M., Hussein N. R., Salih A. M. Infection with H. pylori strains carrying babA2 and cagA is associated with an increased risk of peptic ulcer disease development in Irag // Arab. J. Gastroenterol. - 2012. - Vol. 13, № 4. - P. 166-169.
  7. Gastric Cancer. With Special Focus on Studies from Japan. Editor - Akiko Shiotami. Springer. 2017. - P. 31-63.
  8. Helicobacter pylori. Editor - Nayoung Kim. Springer. 2016. - P. 23-112.
  9. Huang X., Deng Z., Zhang Q. e. a. Relationship between the iceA gene of Helicobacter pylori and clinical outcomes. Ther. Clin. Risk. Manag. - 2016. - № 12. - Р. 1085-1092.

Full text is published :
Spivak E. M., Manyakina O. M., Levit R. M., Kirillov M. Yu., Ogneva L. V., Akkuratova I. S. Genetic characterization of the helicobacter pylori infection in adolescents with chronic gastritis. Experimental and Clinical Gastroenterology. 2019;171(11): 27–30. (In Russ.) DOI: 10.31146/1682-8658-ecg-171-11-27-30
Read & Download full text

1. Gorky Donetsk National Medical University, Donetsk, 283045, Ukraine
2. Husak Institute of Emergency and Reconstructive Surgery, Donetsk, 283045, Ukraine

Keywords: cholelithiasis, hereditary spherocytosis, children

Abstract: Hereditary spherocytosis (Minkowski-Shoffar disease) - protein-dependent mebranopathy, leading to the destruction of red blood cells, is one of the causes of gallstone disease. The purpose of this work: to acquaint doctors of various specialties with a possible complication of hereditary spherocytosis in the form of cholelithiasis. The article briefly presents etiopathogenesis, clinical features, diagnosis and treatment of this disease. Two clinical cases of cholelithiasis with hereditary hemolytic microspherocytic anemia of Minkowski-Shoffar are described.
Results. In the cases presented, there was a severe course of hereditary spherocytosis with hemolytic crises. A detailed picture of suprahepatic jaundice due to microspherocytosis, a decrease in the osmotic resistance of red blood cells, was accompanied by anemia, an increased content of reticulocytes, an increase in the level of indirect bilirubin. The formation of large amounts of thick bile created the conditions for the formation of stones in the gallbladder. Patients had surgical treatment of gallstone disease.
Conclusion: pediatricians, family doctors, hematologists need to remember about the possible complication of hereditary spherocytosis in the form of gallstone disease for forehanded diagnosis and treatment.

• References total 15 ⇓ :: .
  1. Shabalov N. P. Detskaya gastroenterologiya: rukovodstvo dlya vrachey [children’s gastroenterology: the management for doctors]. M.: MEDpress-inform. 2011. 736 р. [In Russian].
  2. Kuvshinnikov V. A., Shenets S. G. Gemoliticheskie anemii u detey: ucheb.-metod. Posobie [Hemolitic anemias at children: educational and methodical grant]. Minsk: BGMU. 2013. 40 р. [In Russian].
  3. Fadeeva O. Yu., Ratmanova G. A., Votyakova O. I., et al. Zhelchnokamennaya bolezn’ u detey, bol’nykh gemoliticheskimi anemiyami [Cholelithiasis at the children sick with hemolitic anemias]. Zemskiy Vrach. 2015, Vol. 27, no. 3, pp. 35-36. [In Russian].
  4. Karaul’ko I. V. Sluchay nasledstvennoy gemoliticheskoy mikrosferotsitarnoy anemii Minkovskogo-Shoffara [Case of hereditary hemolitic microspherocytic anemia of Minkowski-Shoffara]. Problemy zdorov’ya i ekologii. 2008, no. 4, pp. 131-132. [In Russian].
  5. Mikheeva O. M., Akopova A. O., Okhapkina T. G., Ivkina T. I. Gastroenterologicheskie oslozhneniya u bol’nykh s nasledstvennym mikrosferotsitozom [Gastroenterological complications at patients with a hereditary microspherocytosis]. Meditsinskiy alfavit. Prakticheskaya gastroenterologiya. 2015, Vol. 7, no. 1. рр. 44-46. [In Russian].
  6. Pushkareva T. I., Romantsova. E. B. Gemoliticheskie anemii: uchebnoe posobie [Hemolitic anemias: manual]. - Blagoveshchensk: Bukvitsa. 2010. 33 р. [In Russian].
  7. Sokolova T. A. Geneticheskie aspekty nasledstvennykh gemoliticheskikh anemiy (membranopatiy) [Genetic aspects of hereditary hemolitic anemias (membranopathies)]. Uspekhi sovremennogo estestvoznaniya. 2012, no 10. рр. 26-33. [In Russian].
  8. Mitsura E. F. Nasledstvennyy sferotsitoz u detey: sovremennye predstavleniya (obzor literatury) [Hereditary spherocytosis at children: modern representations (overview of literature)]. Problemy zdorov’ya i ekologii. 2011, Vol. 28, no. 2, рр. 39-44. [In Russian].
  9. Mitsura E. F., Volkova L. I. Nasledstvennye gemoliticheskie anemii u detey: printsipy diagnostiki i lecheniya (lektsiya) [Hereditary hemolitic anemias at children: principles of diagnostics and treatments (lecture)]. Problemy zdorov’ya i ekologii. 2013, Vol. 36, no. 2, рр. 25-29. [In Russian].
  10. Nagornaya N. V., Vilchevskaya E. V., Bordyugova E. V., et al. Gemoliticheskie anemii u detey [Hemolitic anemias at children]. Zdorov’ye rebenka. 2013, no. 8, рр. 175-180. [In Russian].
  11. Bondarenko E. M., Kupaeva V. A. Klinicheskiy sluchay sochetaniya nasledstvennogo sferotsitoza s sindromom Zhil’bera [Clinical case of a combination of a hereditary spherocytosis to Gilbert’s syndrome]. Vestnik molodogo uchenogo. 2015, no. 4. рр. 50-53. [In Russian].
  12. Tamary H., Aviner S., Freud E., et al. High incidence of early cholelithiasis detected by ultrasonography in children and young adults with hereditary spherocytosis. J Pediatr Hematol Oncol. 2003; 25(12): 952-954.
  13. Konca Çapan, Söker Murat, Taş Mehmet Ali, Ruken Yıldırım. Hereditary Spherocytosis: Evaluation of 68 Children. Indian J Hematol Blood Transfus. 2015; 31(1): 127-132.
  14. Grona V. N., Litovka V. K., Latyshov K. V., Grona T. G. Zhelchnokamennaya bolezn’ u rebenka s bessimptomnym v anamneze techeniem gemoliticheskoy anemii [Cholelithiasis at the child with the asymptomatic course of hemolitic anemia in the anamnesis]. Zdorov’ye rebenka. 2011, no. 3. рр. 126-128. [In Russian].
  15. Poddubnyy I. V., Evstaf’yeva I.I., Isaev A. A., Tolstov K. N. Laparoskopicheskaya splenektomiya u detey s mikrosferotsitarnoy anemiey i β-talassemiey [Laparoscopic splenectomy at children with microspherocytic anemia and a β-thalassemia]. Rossiyskiy vestnik detskoy khirurgii, anesteziologii i reanimatologii. 2012. Vol. II, no. 4. рр. 11-16. [In Russian].

Full text is published :
Bordyugova E. V., Marchenko E. N., Yuldashevа S. A., Shevtsovа E. I. Cholelithiasis in children with hereditary spherocytosis. Experimental and Clinical Gastroenterology. 2019;171(11): 31–35. (In Russ.) DOI: 10.31146/1682-8658-ecg-171-11-31-35
Read & Download full text

1. Sechenov First Moscow State Medical University 8–2, Trubetskaya St., Moscow, Russian Federation, 119991
2. Russian National Research Medical University N. I. Pirogov, Ministry of Health of Russia, Moscow, Russia
3. State budget organization of public health service “Children’s city polyclinic № 99 of public health department of the city of Moscow”, fi lial № 2, Staroalekseevskaya St. h.18, Moscow, Russia

Keywords: medical organization, situational analysis, SWOT analysis, healthy child’s offi ce, health programming, counseling, prevention, health-saving technologies, nurses with higher education, nursing education

Abstract: The aim is to analyze the activities of nurses in the offices of a healthy child in children’s policlinics in Moscow to optimize counseling and improve the quality of preventive work.
Materials and methods. The data of official statistics and statistical reports of the office of a healthy child clinic. The method of statistical analysis of data for the study period, analysis of medical services and quantitative method of SWOT-analysis of 75 parents of children who visited the office of a healthy child.
Results and discussion. Analysis of the office of a healthy child clinic revealed additional opportunities for the organization of primary prevention of gastroenterological diseases. It was found that the leading position on perenatal counselling is given to the nurse, and nurses with higher medical education have the advantage. It is advisable to revise the regulatory framework for the functioning of the Cabinet of healthy child and provide modern equipment, the introduction of modern methods of organization of work taking into account the training/retraining of nurses with higher education. In the course of advisory and educational work, a nurse with higher education uses the accumulated psychological and pedagogical skills, and parents receive professional information on the development of young children, which ultimately ensures the introduction of new health-saving technologies into practice.
Conclusion. The results of the situational analysis of the activities of a nurse in a healthy child’s office allow us to optimize the process of counseling the speed of decision-making to improve the quality of preventive work in a children’s policlinic.

• References total 11 ⇓ :: .
  1. Resolution of the Government of the Russian Federation of April 15, 2014 No. 294 “On Approval of the State Program of the Russian Federation“ Health Care Development ” (Meeting of the Legislation of the Russian Federation of April 28, 2014 No. 17, Art. 2057).
  2. Zaprudnov A. M., Grigoriev K. I., Kharitonova L. A., Bogomaz L. V. Modern aspects of the prevention of diseases of the digestive system in children. Experimental and clinical gastroenterology. 2013; № 1: 3-14.
  3. Leschenko M. V., Derinova E. A., Makarova Z. S., et al. The cabinet of a healthy child in terms of health care reform. Vopr perinatol and pediatrician. 2017; 62: (6): 104-109.
  4. Goncharova O. V. Educational programs for the care of a child in the offices of a healthy child in children’s health care facilities. Medizinskyi sovet (Medical advice). 2013. № 1: 73-79.
  5. Order of the Ministry of Health of the Russian Federation No. 267 dated August 16, 2002 «On Making Addenda to the Order of the Ministry of Health of Russia dated August 27, 1999 No. 337 «On the Nomenclature of Specialties in Health Care Institutions of the Russian Federation».
  6. Methodical recommendations «The organization of the work of the office of a healthy child in a children’s clinic» (approved by the Ministry of Health of the USSR of 23.03.1987 No. 11-11 / 6-25).
  7. Zubkova N. Z., Skvortsova E. S., Prilepina I. A., Leshchenko M. V. Organization of the work of the study of a healthy child in the children’s clinic. Guidelines. M., 2007: 72 р.
  8. Order of the Ministry of Healthcare and Social Development of the Russian Federation dated July 23, 2010 No. 541n «On the approval of the qualification reference book of managers, specialists and employees, the section «Qualification characteristics of employees in the field of health care».
  9. Order of the Ministry of Education and Science of the Russian Federation No. 964 of September 3, 2015 «On Approval of the Federal State Educational Standard for Higher Vocational Education in the Direction of Training 34.03.01 Nursing (Bachelor’s degree)» [Electronic resource]. Portal of the Federal State Educational Standards of Higher Education.
  10. Order of the Ministry of Health of the Russian Federation of 05.06.1998 No. 186 «On the upgrading of skills of specialists with secondary medical and pharmaceutical education», as amended by the order of the Ministry of Health of Russia No. 332 dated August 5, 2003.
  11. Aleksandrova O. V., Vasnetsova O. A. Marketing research nursing care. Medizinskaya Sestra (Nurse). 2010;7: 7-9.

Full text is published :
Nemtyryova L. F., Grigoriev K. I., Balashova I. V. Marketing analysis of the role of a nurse in counseling parents in the offi ce of a healthy child in children's polyclinic. Experimental and Clinical Gastroenterology. 2019;171(11): 36–43. (In Russ.) DOI: 10.31146/1682-8658-ecg-171-11-36-43
Read & Download full text

1. State Pediatric Medical University, Ministry of Healthcare of the Russian Federation, Saint Petersburg, Russia

Keywords: children, hereditary diseases, hereditary liver diseases, diagnosis, principles of therapy

Abstract: In the genesis of the development of chronic liver and liver diseases in childhood insufficiency, the leading place belongs to hereditary liver diseases. Timely diagnosis allows you to identify this pathology at an early age and choose the right treatment tactics, and improve the prognosis. The article presents a modern view of diseases such as alpha 1-antitrypsin deficiency, neonatal hemochromatosis, erythropoietic protoporphyria, cystic fibrosis. The treatment of such diseases should be comprehensive, based on the principle of an interdisciplinary approach.

• References total 20 ⇓ :: .
  1. Sveger T. Liver disease in alpha-1-antitrypsin deficiency detected by screening of 200000 jnfants. N Engl J Med 1976; 294:1316-1321.
  2. Sveger T. Alpha-1-antitrypsin deficiency in early childhood. Pediatrics 1978; 62:22-25.
  3. Prachallas A. A., Kalife M., Francavilla R. et al. Liver transplantation for alpha-1-antitrypsin deficiency in children. Transpl Int 2000:13:207-210
  4. Qu D, Teckman JH, Perimutter DH, Review: Alpha-1-antitrypsin deficiency associated liver disease. J Gastroenterol Hepatol 1997; 12:404-416.
  5. Perlmutter DH, Brodsky JL, Balistreri WF, Trappel BC. Molecular pathogenesis of alpha-1-antitrypsin deficiency-associated liver disease: a meeting review. Hepatology 2007; 45:1313-1323.
  6. Kayler L.K, Rasmussen CS, Dykstra DM, Punch JD, Rudich SM, Magee Js. Liver transplantation in children with metabolic disorders in the US. Am J Transplant 2003; 3:334-339.
  7. Sigurdsson L, Reyes J, Kocoshis SA, Hansen TW, Rosh J, Knisely AS. Neonatal hemochromatosis: outcomes of farmacologic and surgical therapies. J Pediatr Gastroenterol Nutr 1998; 26: 85-89.
  8. Bonilla S, Prozialeck JD, Malladi P, Pan X, Yu S, Melin-Aldana H, Whitington PF. Neonatal iron overload and tissue siderosis due to gestational alloimmune liver disease. J Hepatol 2012; 56: 1351-1355.
  9. Taylor SA, Whitington PF. Neonatal Acute Liver Failure. Liver Transplantation 2016; 22: 677-685.
  10. Grabhorn E, Richter A, Burdelski M, Rogiers X, Ganschou R. Neonatal haemochromatosis: long term experience with favorable outcome. Pediatrics 2006; 118: 2060-2065.
  11. Heissat S, Collardeau-Frachon S, Baruteau J, Dubruc E, Bouvier R, Fabre M. Neonatal hemochromatosis diagnostic work-up based on a series of 56 cases of fetal death and neonatal liver failure. J Pediatr 2015;166:66-73.
  12. Whitington PF. Neonatal haemochromatosis: a congenital alloimmune hepatitis. Semin Liver Dis 2007; 27:243-250.
  13. Whitington PF, Hibbard JU. High dose immunoglobulin during pregnancy for reccurent neonatal haemochromatosis. Lancet 2004; 364:1690-1698.
  14. Murray KF, Kowdlay KV. Neonatal hemochromatosis. Pediatrics 2001; 108:960-964.
  15. Bloomer JL, Bonkowsky HL, Ebert PS, Mahoney MJ. Inheritance in protoporphyria. Comparison of haem synthetase activity in skin fibroblasts with clinical features. Lancet 1976; 2:226-228.
  16. Meerman L, Koopen NR, Bloks V, Van Goor H, Havinga R, Wolthers BG. Biliary fibrosis associated with altered byle composition in a mouse model of erythropoietic protoporphyria. Gastroenterology 1999; 117:696-705.
  17. Pirlich M, Lochs H, Schmidt HH. Liver cirrhosis in erythropoietic protoporphyria: improvement of liver function with ursodeoxycholic acid. Am J Gastroenterol 2001; 96: 3468-3469.
  18. McGuireBM, Bonkovsky HL, Carthers RLJr, Chung RT, Goldstain LI, Lake JR. Liver transplantation for erythropoietic protoporphyria liver disease. Liver Transpl 2005; 11:1590-1596.
  19. Rowe SM, Miller S, Sorschr EJ. Cystic fibrosis. N Eng J Med 2005; 352:1992-2001.
  20. Colombo C, Russo MC, Zazzeron L, Romano G. Liver disease in cystic fibrosis. J pediatr Gastroenterol Nutr 2006; 43(suppl1):49-55.

Full text is published :
Revnova M. O., Gaiduk I. M., Bairova S. V., Koltunceva I. V., Mishkina T. V., Ivanov D. O. Hereditary diseases of the liver of the neonatal period. Experimental and Clinical Gastroenterology. 2019;171(11): 44–50. (In Russ.) DOI: 10.31146/1682-8658-ecg-171-11-44-50
Read & Download full text

1. Ivanovo State Medical Academy, Ivanovo, Russia

Keywords: children, regular medical examination, ulcerative colitis, Crohn’s disease

Abstract: Schedules of regular medical checkups for children with ulcerative colitis and Crohn’s disease by paediatricians and medical specialists, of laboratory and instrumental examinations are offered, a complex of prophylactic, therapeutic and rehabilitation measures is described. Key aspects of the programme are its complex character, continuity, division into stages and use of modern diagnostic methods. Problems of diet therapy, medication and many other aspects of the follow-up of children with ulcerative colitis and Crohn’s disease are discussed. Criteria of the effectiveness of the programme are: the absence of exacerbations and omplications of diseases, normal physical and sexual development of a child, improvement of the quality of the patient’s life.

• References total 14 ⇓ :: .
  1. Pediatric Gastroenterology. Editors S. V. Belmer A. I. Havkin, P. L. Scherbakov. Moscow, MEDPRACTICA -M, 2010. 476 p.
  2. Pediatric Gastroenterology. Editors N. D. Shabalov. Moscow, MEDpress- inform, 2013. 760 p.
  3. Pediatric Gastroenterology: practical guidance. Editor I. Yu. Melnikova. Moscow. GEOTAR-media, 2017. 480 p.
  4. Clinical recommendations of the Russian Ministry of Health. Ulcerative colitis at children. Moscow, 2016. 53 p.
  5. Clinical recommendations. Identification of level of calprotectin in the coprofiltrates for differential diagnostics and monitoring of efficiency of treatment of patients with inflammatory diseases of intestines. Moscow, 2015. 10 p.
  6. The order of the Russian Ministry of Health dated 21.03.2017 no. 124n «Concerning the statement of an order and terms of carrying out routine medical examinations of citizens for detection of tuberculosis».
  7. Pediatric Clinical nutrition. Editors T. E. Borovik, K. S. Ladodo. Moscow, MIA, 2008. 606 p.
  8. The order of the Russian Ministry of Labour and Social Protection dated 17.12. 2015 no. 1024n “Concerning the classifications and criteria used during the implementation of medical and social examination of citizens by federal state institutions of medical and social examination”.
  9. Methodological guidelines of the Russian Ministry of Health 3.3.1879-04 “Immunoprophylaxis of infectious diseases. The investigation of vaccination complications”.
  10. Methodological guidelines of the Russian Ministry of Health 3.3.1.1123-02 “Monitoring of post-vaccination complications and their prevention”.
  11. Methodological guidelines of the Russian Ministry of Health 3.3.1.1095-02 “Medical contraindications to carrying out preventive inoculations by means of preparations of the national calendar”.
  12. Recommendations of the society of pediatric gastroenterologists, hepatologists and nutritionists. Rehabilitation of children with digestive disorders. Proceedings of the XXIV International Congress of Pediatric Gastroenterologists of Russia and CIS “Actual problems of abdominal pathology in children”. Editors S. V. Belmer, L. I. Ilyenko. Moscow, MEDPRAKTIKA-M, 2017. pp. 208-257.
  13. Recommendations for the medical care of students “Control over the compliance with sanitary and hygienic requirements for the conditions and organization of physical education in educational institutions”. Moscow, 2014; 38 p.
  14. The order of the Russian Ministry of Health dated 18.08.2017 no. 514 “On the procedure for preventive medical examinations of minors”.

Full text is published :
Rusova T. V., Ratmanovaga G. A. Regular medical examination of children with ulcerative colitis and Crohn’s disease. Experimental and Clinical Gastroenterology. 2019;171(11): 51–58. (In Russ.) DOI: 10.31146/1682-8658-ecg-171-11-51-58
Read & Download full text

1. Bashkir state medical University, Ufa, Russian Federation Republic, Ufa, Russia

Keywords: Cholelithiasis, X-ray computer tomography, pediatric surgery, laparoscopic cholecystectomy, children

Abstract: The aim was investigate some features of diagnosis of cholelithiasis in children. Materials and methods: The study was completed with 75 patients in the Clinic of pediatric surgery of the BSMU, Russia, Ufa in 1997-2017. The mean age of the patients was 11.2±3.8 (3-18) years. 44 (58.7%) patients were females. Results: The original method (X-ray Tomography with cholekinentic) was preferred and received results were decisive for surgery. Identified sclerotic changes (>40 H) and gallstone density (>100H) were indications for cholecystectomy.

• References total 14 ⇓ :: .
  1. Khavkin A.I., Kharitonova L.A. Diseases of the biliary tract. Gastroenterology of childhood. Moscow. Medical practice. 2003, pp.279-329.
  2. Zaprudnov A.M., Kharitonova L.A. Features of cholelithiasis in childhood, Freiburg: Falk Pharma GmbH, 2002. 52 P.
  3. Lupash N.G., Kharitonova L.A., Shakaryan K.A. Gallstone disease in young children - should be treated conservatively or promptly? Grew. Bulletin of Perinatology and Pediatrics. 2018. Vol.64, No. 4, pp. 63-68.
  4. Ilchenko A. A. Diseases of the gallbladder and bile ducts: a Guide for doctors.-2nd ed. recycled. Moscow. LLC “Publishing house “Medical Information Agency”, 2011. 880 P.
  5. Dronov A.F., Poddubny I.V., Zalikhin D.V., Chundokova M.A., Al-Mashat N.A. Experience of the first 100 laparoscopic cholecystectomies in children. Endoscopic surgery. 2000, Volume 6, No. 1, pp. 25-33.
  6. Ahmad G, O’Flynn H, Duffy JMN, et al. Laparoscopic entry techniques. Cochrane Database Syst Rev 2012; 2: CD006583.
  7. Nougues CP, Harmon CM, Hansen EN, et al. Cholecystectomy using single-incision pediatric endosurgery: Technique and initial experience in the first 25 cases. J Laparoendosc Adv Surg Tech A 2010; 20:493-6.
  8. Frybova B, Drabek J, Lochmannova J, et al. Cholelithiasis and choledocholithiasis in children; risk factors for development. PLoS One. 2018 May 15;13(5): e0196475.

Full text is published :
Alyangin V. G., Sataev V. U., Viktorov V. V., Nizhevich A. A., Latypova G. G. Features of diagnosis of cholelithiasis in children. Experimental and Clinical Gastroenterology. 2019;171(11): 59–63. (In Russ.) DOI: 10.31146/1682-8658-ecg-171-11-59-63
Read & Download full text

1. Federal State Budgetary Educational Institution of Higher Education “Northern State Medical University” of the Ministry of Healthcare of the Russian Federation, Troitskiy ave, Arkhangelsk, 163000, Russia
2. State budgetary healthcare institution “Arkhangelsk Children’s clinical Hospital”, Obvodniy Kanal ave, 7, Arkhangelsk, 163002, Russia
3. Federal State Budgetary Educational Institution of Higher Education “Tula State University”, Lenina ave, 92, Tula, 300012, Russia
4. Federal State Budgetary Educational Institution of Higher Education “A. I. Yevdokimov Moscow State University of Medicine and Dentistry” of the Ministry of Healthcare of the Russion Federation, Delegatskay str., 20\1, Moscow, 127473, Russia

Keywords: Newborn intestinal obstruction, interventional methods of ultrasound, hydrocolonic sonography

Abstract: The main methods of diagnostics newborn intestinal obstruction (NIO) is radiological. Ultrasonography (US) plays a supporting role when carrying out differential diagnostics.
Purpose: to estimate possibilities of diagnostics and treatment of children with NIO and its complications with use special interventional methods of US.
Methods: Retrospective study of results of the treatment children with NIO operated in the Arkhangelsk children’s hospital in 1998-2012 was conducted, in 62 the protocol of investigation included special US methods. Two groups were compared: 1st (n=44) for the purpose of diagnostics of NIO and its reasons special US methods (US of the stomach with contrasting by fluid, hydrocolonic sonography (HS)) and X-RAY carried out, 2nd (n=44) were only radiological investigations. In both groups timeliness of establishment of the diagnosis and a postoperative lethality were estimated.
Results: All types of NIO and their complications had direct signs (visualization of the atresia, volvulus, exudate at peritonitis, violation of a passage in underlying departments of a gastrointestinal tract) and indirect US signs allowing to make a conclusion about obstruction reason. In the 1st group the diagnosis of NIO was significantly more often made in time (p <0,001), statistically significantly was less often observed lethal outcome, than in patients of the 2nd group (p <0,001).

• References total 25 ⇓ :: .
  1. Isakov YU.F., Dronov A. F. Detskaya khirurgiya: natsional’noye rukovodstvo [Pediatric surgery: National guidelance]. Moscow, Medicina: GEOTAR-Media, 2009. 1168 p.
  2. Holcomb G.W., Murphy P. J. Ashcraft’s pediatric surgery. Ostlie - 6th Ed., Elsevier Inc., 2014. 1192 р.
  3. Glasser J. G. Intestinal obstruction in the newborn. Available at: http://emedicine.medscape.com/article/2066380-overview (accessed Mar 17 2016).
  4. Pykov M. I. Detskaya ul’trazvukovaya diagnostika. [Children’s ultrasound diagnostics]. Moscow, Vidar, 2015. 680 p.
  5. Dvoryakovsky I. V., Sugak A. B. Ul’trazvukovaya diagnostika pri sindrome srygivaniya i rvoty u novorozhdonnykh i detey grudnogo vozrasta [Ultrasound diagnostics for regurgitation and vomiting syndrome in newborns and infants]. Ultrasound and Functional Diagnostics, 2007, no. 1, pp. 84-92 (in Russ).
  6. Magu S, Rattan K. N., Sharma N. Image: Whirlpool sign midgut volvulus (An US diagnosis). Indian J. Radiol. Imaging. 2001; 11(4): 205-206.
  7. Yanitskaya M. Yu., Kudryavtsev V. A., Sapozhnikov V. G., et al. Ekhograficheskoye issledovaniye polykh organov zheludochno-kishechnogo trakta pri khirurgicheskoy patologii u detey. Gidroekhokolonografiya. [Ultrasound examination of the of the gastrointestinal tract in surgical pathology in children. Hydrocolonic echography]. Arkhangelsk: Publishing House of NSMU, 2013, 129 p.
  8. Medvedev M. V. Prenatal ultrasound. Medicina: Real time, 2005, 560 p.
  9. Kucherov Yu.I., Dorofeeva E. I., Zhirkova Yu.V., et al. Opyt lecheniya patsiyentov s vrozhdonnoy kishechnoy neprokhodimost’yu v usloviyakh perinatal’nogo tsentra [Experience in treating patients with congenital intestinal obstruction in a perinatal center]. Pediatric Surgery, 2009, no. 5, pp. 11-16 (in Russ).
  10. Carlyle B.E., Borowitz D. S., Glick P. L. A review of pathophysiology and management of fetuses and neonates with meconium ileus for the pediatric surgeon. J Pediatr surg. 2012; 47: 772-781. doi: 10.1016/j.jpedsurg.2012.02.019
  11. Penco J.M.M., Murillo J. C., Hernandez A., et al. Anomalies of intestinal rotation and fixation: consequences of late diagnosis beyond two years of age. Pediatr. Surg. Int. 2007; 19: 544-547. doi: 10.1007/s00383-007-1972-0
  12. Ratan S.K., Rattan K. N., Maheshwari J., et al. Acquired ileal atresia in infancy: report of two cases. Pediatr. Surg. Int. 2005; 23: 723-730. doi:10.1007/s00383-005-1373-1
  13. Kimura K., Loening-Baucke V. Bilious vomiting in the newborn: Rapid diagnosis of intestinal obstruction. J. Am. Fam. Physician. 2000; 61: 2791-2798.
  14. Grona V. N., Zhurilo I. P., Perunsky V. P., et al. Narusheniya fiksatsii i rotatsii kishechnika u novorozhdonnykh [Disorders of fixation and rotation of the intestine in newborns]. Clinical Anatomy and Surgery, 2007, no. 6, pp. 29-33 (in Russ).
  15. Gilbertson-Dahdal D.L., Dutta S., Varich L. J., et al. Neonatal malrotation with midgut volvulus mimicking duodenal atresia. AJR Am. J. Roentgenol. 2009; 192: 1269-1271. doi: 10.2214/AJR.08.2132
  16. Mehall J.R., Chandler J. C., Mehall R. L., et al. Management of typical and atypical intestinal malrotation. J Pediatr. Surg. 2002; 37: 1169-1172.
  17. Epelman M., Daneman A., Navarro O. M., et al. Necrotizing Enterocolitis: Review of State-ofthe-Art Imaging Findings with Pathologic Correlation. RadioGraphics. 2007; 2: 285-305.
  18. Khamatkhanova E. M. Puti sovershenstvovaniya kachestva meditsinskoy pomoshchi pri vrozhdonnykh porokakh razvitiya. Diss. dokt. med. nauk. [Ways to improve the quality of medical care for congenital malformations. Dr. med. scie. diss.]. Moscow, 2011. 315 p.
  19. Walker G.M., Neilson A., Young D., et al. Colour of bile vomiting in intestinal obstruction in the newborn: questionnaire study. BMJ; 7554(332): 1363. doi:10.1136/bmj.38859.614352.55
  20. Arapova A. V., Olkhova E. B., Shchitinin V. E. Nekroticheskiy enterokolit u novorozhdonnykh. [Necrotizing enterocolitis in newborns]. Pediatric Surgery, 2003, No. 1, pp. 11-15. (in Russ).
  21. Dimmitt R.A., Moss R. L. Meconium diseases in infants with very low birth weight. Semin. Pediatr. Surg. 2000; 9: 79-83.
  22. Keeney S.E., Angel C. A., Thompson L. L., et al. Meconium obstruction in the very low birth weight premature infant. J. Pediatrics. 2004; 114: 285-290.
  23. Olkhova E. B. Options for echographic representation of Ledd’s syndrome in newborns. Pediatric Surgery, 2013, No. 5, pp. 16-20.
  24. Yeh W.C., Wang H. P., Chen C., et al. Preoperative sonographic diagnosis of midgut malrotation with volvulus in adults: the ‘‘whirlpool’’ sign. J. Clin. Ultrasound. 1999; 27: 279-283.
  25. Chao H.C., Kong M. S., Chen J. Y., et al. Sonographic features related to volvulus in neonatal intestinal malrotation. J Ultrasound Med. 2000;19: 371-376.

Full text is published :
Yanitskaya M. Y., Sapozhnikov V. G., Poddubnyi I. V. Diagnostics and treatment of newborn intestinal obstruction with use of methods of interventional ultrasound. Experimental and Clinical Gastroenterology. 2019;171(11): 64–71. (In Russ.) DOI: 10.31146/1682-8658-ecg-171-11-64-71
Read & Download full text

1. Kazan State Medical University, 420012, Kazan, 49 Butlerova str
2. Federal Scientifi c Clinical Center of Sports Medicine and Rehabilitation of FMBA, 121059, Moscow, 5 Bolshaya Dorogomilovskaya Str.

Keywords: young athletes, carnitine, amino acids, fat percentage

Abstract: The objective: To study the features of carnitine and amino acid metabolism in young athletes.
Materials and methods: 131 children (I-II health groups) aged 12 to 17 years 11 months were examined. The main group is 94 young athletes. Control group - 37 children who do not engage in sports. Determination of the level of free and bound carnitine, amino acids by tandem chromatography-mass spectrometry.
According to the results of the examination of two groups of children, the content of free carnitine is significantly higher in young athletes (p <0.05). Significant differences exist in the free / bound carnitine index. This figure is significantly higher among athletes (p <0.05). The reliability of differences in the content of methionine was noted at p Conclusion indicate the presence of a number of features of carnitine status and amino acid metabolism in young athletes. It can be assumed that the obtained data reflect a more efficient cellular energy in children involved in sports.

• References total 5 ⇓ :: .
  1. Biktimirova A. A., Rylova N. V., Zolkina I. V. et al. Carnitine metabolic features in young athletes. Russian Bulletin of Perinatology and Pediatrics. 2015, vol. 60, no. 2, pp.105-107 (In Russ.)
  2. Biktimirova A. A., Rylova N. V., Samoilov A. S. Application of cardiorespiratory exercise testing in sports medicine. Practical Medicine. 2014, vol. 79, no. 3, pp. 50-53 (In Russ.)
  3. Rylova N. V., Biktimirova A. A., Imamov A. A., Zholinsky A. V. Topical Questions of Medical and Biological Support of Children’s and Youth Sports. Ros Vestn Perinatol i Pediatr. 2018; vol. 63, no. 5, pp 231-236. (in Russ). DOI: 10.21508/1027-4065-2018-63-5-231-236
  4. Orer G., Guzel N. The effects of acute L-carnitine supplementation on endurance performance of athletes. J Strength Cond Res. 2014, vol. 28, no. 2, pp. 514-519. DOI: 10.1519/ JSC.0b013e3182a76790
  5. Karlic H, Lohninger A. Supplementation of L-carnitine in athletes: does it make sense? Nutrition. 2004; no. 7, pp. 709-715. DOI:10.1016/j.nut.2004.04.003.

Full text is published :
Rylova N. V., Zholinsky A. V. Indices of exchange of carnitinum and amino acids in young sportsmen. Experimental and Clinical Gastroenterology. 2019;171(11): 72–75. (In Russ.) DOI: 10.31146/1682-8658-ecg-171-11-72-75
Read & Download full text

1. Pirogov Medical University, Moscow, Russia
2. State Clinical hospital № 29 them. Baumann, Моscow, Russia

Keywords: microbiota, obesity, dyslipidemia

Abstract: The gut microbiota has attracted increasing attention during the last several years as a key player in the pathophysiology of chronic disease. Microbiome is considered to be the link between metabolic disorders, obesity, insulin resistance, dyslipidemia, diabetes, hypertension and cardiovascular diseases. Recent findings have related the intestinal microbiota to a plethora of pathological conditions, including type 2 diabetes, obesity, cholelithiasis and nonalcoholic steatohepatitis. This review presents potential mechanisms for the development of these diseases in response to changes in the gut microbiota. They involve increased gut permeability, low-grade inflammation and autoantibodies. Many studies contradict each other, which confirms the need for further scientific research in this area.

• References total --- ⇓ :: .
   

Full text is published :
Kharitonova L. A., Papisheva О. V., Mayatskaya T. A., Kotaysh G. A. State of the micro-biota of bowels with dislipidemii in the children. Experimental and Clinical Gastroenterology. 2019;171(11): 76–82. (In Russ.) DOI: 10.31146/1682-8658-ecg-171-11-76-82
Read & Download full text

1. Russian National Research Medical University N. I. Pirogov, Ministry of Health of Russia, Moscow, Russia, 1 Ostrovityanova st. Moscow 117997
2. Children΄s City Clinical Hospital Z. A. Bashlyaevoy, 28 Heroes of Panfi lov st Moscow 125373

Keywords: Albendazole, drug- induced liver injury, liver, drug, children

Abstract: A case of the drug-induced liver injury (DILI) development is presented on the background of the self-treatment with an antiparasitic drug Albendazole in an 11 years-old girl with several risk factors for the drug-induced liver injury (history of a drug reaction, carbohydrate and fat metabolism disturbance, female gender, and adolescence). The disease was diagnosed using the the CIOMS/RUCAM scale. The drug was withdrawn and the pathogenetic therapy was established (fluids, hepatoprotective drugs) with the resolution of the drug-induced hepatitis.

• References total 8 ⇓ :: .
  1. Homeriki S. G., Homeriki N. M. Drug-induced liver injury. Training manual for physicians. Moscow: Forte-Print 2012; 23. (in Russ)
  2. Borzakova S. N., Aksjonova V. A., Rejzis A. R. Literature Review: Drug-induced hepatic injury in children with tuberculosis. Tuberkulyoz i bolezni legkih. 2010; 8: 3-12. (in Russ)
  3. Drug-induced liver damage. Clinical practice guidelines for doctors / KL Raykhelson, LK Palgova, EA Kondrashin et al. - Moscow, MEDpress-Inform, 2018. - 80 p.
  4. Gubergrits, NV Belyaeva, AE Klochkov, et al. Drug-induced liver disease: from pathogenesis to treatment: manual. M.: Prima Print, 2018. - 36 p.
  5. Molochkova OV, Kovalev OB, Uchaikin VF, et al. Drug-induced hepatitis in children. Childhood infections, 2017, pp. 42-51
  6. Danan G1, Teschke R. Drug-Induced Liver Injury: Why is the Roussel Uclaf Causality Assessment Method (RUCAM) Still Used 25 Years After Its Launch? / Drug Saf. 2018 Aug;41(8): 735-743. doi: 10.1007/s40264-018-0654-2.
  7. Borzakova S. N., Aksjonova V. A., Rejzis A. R. Pathogenetic approaches to the treatment of drug-induced hepatic injury in tuberculosis in children. Ros vestn perinatol i pediatr. 2013; 58 (6): 74-79. (in Russ)
  8. Bilgic Y, Yilmaz C, Cagin YF, Atayan Y, Karadag N, Harputluoglu MM. Albendazole Induced Recurrent Acute Toxic Hepatitis: A Case Report / Acta Gastroenterol Belg. 2017 Apr-Jun; 80(2): 309-311.

Full text is published :
Borzakova S. N., Kharitonova L. A., Ermakova M. N., Osmanov I. M., Rudikova E. V. Albendazole-induced liver injury of a 11-year-old girl. Experimental and Clinical Gastroenterology. 2019;171(11): 83–88. (In Russ.) DOI: 10.31146/1682-8658-ecg-171-11-83-88
Read & Download full text

1. FGBOU IN RNIMU them. N. I. Pirogova of the Ministry of Health of Russia, 117997, Moscow, Russia
2. RCCH FSBEI IN RNIMU them. N. I. Pirogova of the Ministry of Health of Russia, 119571, Moscow, Russia

Keywords: cystic fi brosis, food allergy, sensitization of children

Abstract: Cystic fibrosis is a hereditary disease that affects the quality of life of patients without proper treatment. It has been established that allergic diseases have become a global public health problem. Due to a variety of clinical manifestations that affect the development, health and quality of life, it is difficult to diagnose. Due to the high incidence of allergic problems, there is the problem of interrelationship of hereditary genetic diseases - cystic fibrosis and spectral sensitization of children suffering from morbidity in order to improve the algorithms, improve the condition and quality of life of patients, due to the appointment of proper diet therapy.

• References total 9 ⇓ :: .
  1. Horsley A. Book review: Hodson and Geddes’ Cystic Fibrosis. Breathe (Sheff). 2016;12(1):91-92. doi:10.1183/20734735.000216
  2. Tatochenko V.K., Rachinsky S.V., Volkov I.K., Fedorov A.M. Practical pulmonology in children: A Handbook. Moscow. 2006.250 p.
  3. Asherova I.K., Kapranov N.I. Cystic fibrosis - a medical and social problem. M., Yaroslavl: Printing House, 2013: 236 p.
  4. Cutting GR. Cystic fibrosis genetics: from molecular understanding to clinical application. Nat Rev Genet. 2014;16(1):45-56. doi:10.1038/nrg3849
  5. World Health Organization, Global Observation, Prevention and Control of Chronic Respiratory Diseases: Integrated Approach, 2007. Available at: www.who.int/gard/publications/GARD Book 2007.pdf
  6. Loh W, Tang MLK. The Epidemiology of Food Allergy in the Global Context. Int J Environ Res Public Health. 2018;15(9):2043. Published 2018 Sep 18. doi:10.3390/ijerph15092043
  7. Chong SN, Chew FT. Epidemiology of allergic rhinitis and associated risk factors in Asia. World Allergy Organ J. 2018;11(1):17. Published 2018 Aug 6. doi:10.1186/s40413-018-0198-z
  8. Yue D, Ciccolini A, Avilla E, Waserman S. Food allergy and anaphylaxis. J Asthma Allergy. 2018;11:111-120. Published 2018 Jun 20. doi:10.2147/JAA.S162456
  9. Gupta R. S., Springston E. E., Warrier M. R., Smith B., Kumar R., Pongracic J., Holl J. L. (2011). The prevalence, severity, and distribution of childhood food allergy in the United States. Pediatrics, 128, e9-e17. doi: 10.1542/peds.2011-0204

Full text is published :
Antonova E. A., Goryainova A. V., Semykin S. Yu., Filatova T. A. The spectrum of sensitization of children with cystic fi brosis. Experimental and Clinical Gastroenterology. 2019;171(11): 89–92. (In Russ.) DOI: 10.31146/1682-8658-ecg-171-11-89-92
Read & Download full text

1. Saratov State Medical University, n. a. V. I. Razumovsky of the Ministry of Health of Russia, Russia, Saratov, B .Kazachja, 112, 410012

Keywords: peptic ulcer, symptomatic ulcer, complications of peptic ulcer, prepyloric stenosis

Abstract: In the article, the authors present brief information about gastric ulcer and duodenal ulcer, its epidemiology, diagnostic capabilities, approaches to the treatment and prevention of complications. In addition, there are data on the diagnosis and verification of symptomatic gastroduodenal ulcers. Using the example of a clinical case of a complicated symptomatic ulcer in a child, the authors describe the difficulties encountered at the stages of diagnosis, treatment, and follow-up at high risk of complications.

• References total 31 ⇓ :: .
  1. Clinical recommendations Peptic ulcer of the stomach and / or duodenum in children. Moscow. -2016. 34 p.
  2. Maksimov V. A. Modern therapy of diseases of the digestive system. -M: Publishing House Adamant, 2011. 712 p.
  3. Zhukova E. A. Morphofunctional and immunological characteristics of the mucous membrane in duodenal ulcers in children. Ros. Pediatric. journal. 2004, no. 2, pp. 23-26.
  4. Vidmanova T. A., Zhukova E. A., Kulik N. N. Dynamics of morphofunctional changes in the esophagogastroduodenal mucosa during therapy peptic ulcer in children. http://www.gastroportal.ru/php/content.php?id=113169&pr=print
  5. Belmer S. V., Khavkin A. I. Gastroenterology of children’s age. Practical guidelines on childhood diseases. Ed. V. F. Kokolina, A. G. Rumyantsev. - M: Medpraktika, 2003. - № 2. - p.121-149
  6. Klyuchnikov O. O. Features of the clinical course and treatment of PUD in children. Collection of articles on gastroenterology. - 2006. - p.43-50.
  7. Belmer S. V. Perspectives of pediatric gastroenterology. Perspectives of medicine. Practice pediatrician. 2013, March-April, pp.7-10.
  8. Tsvetkova L. N., Filin V. A., Nechaeva L. V., Goryacheva O. A., Gureev A. N. Peptic ulcer in children: features of the course and choice of drug therapy at the present stage. Ros. Vestn. Perinat. and pediatrics. 2008, no. 5: 36, p.42.
  9. Grigoriev K. I., Zaprudnov A. M., Kharitonova L. A. Peptic ulcer - historical dynamics of views on the etiopathogenesis and treatment from the pediatrician’s point of view. Experimental and Clinical Gastroenterology. 2019, no. 161 (1), pp.155-165.
  10. Zimmerman Y. S. Peptic ulcer: a critical analysis of the current state of the problem. Experimental and clinical gastroenterology. 2018, no. 149 (1), pp.80-89.
  11. Zaprudnov A. M., Grigoriev K. I., Kharitonov L. A., Bogomaz L.V, Yudina T. M. Problems and prospects of modern children’s gastroenterology. Pediatrics. 2016, vol. 95, no. 6, pp. 10-18.
  12. Diseases of the digestive system in children. A guide for physicians. A. V. Mazurin (ed.). Moscow: Medicine, 1984; 656 p.(in Russ)
  13. Privorotsky V. F., Luppova N. E. Acid-related diseases in children (clinical presentation, diagnosis, treatment): Proc. allowance. 2nd ed., Rev. and add. - SPb.: Ed. House SPbMAPO, 2005
  14. Kalinin A. V., Loginov A. F. Symptomatic gastroduodenal ulcers. Farmateka. 2010, no. 2, pp.38-45.
  15. Kalinin A. V. Symptomatic gastroduodenal ulcers and peptic ulcer disease: what are the similarities and differences?. Ross.zhurn.gastroenterolog., hepatolog., coloproctology. 2008, vol. 18, no.1, p.5-68
  16. Argunova I. A. Symptomatic gastroduodenal ulcers (lecture for general practitioners). Bulletin of Smolensk State Medical Academy. 2014, vol. 13, no. 3, pp.125-134.
  17. Belousov Yu. V. Pediatric gastroenterology: peptic ulcer or symptomatic ulcer? Child health. 2012, no. 4 (39), pp.121-128.
  18. Roth S. H. Nonsteroidal anti-inflammatory drug gastropathy. We started it - can we stop it? Archives of Internal Medicine. 1986, vol. 146, pp.1075-1076.
  19. Nasonov V. A. Gastropathy associated with the intake of nonsteroidal anti-inflammatory drugs. Russian journal of gastroenterology and hepatology. 1994, vol. 3, no. 1, pp. 7-10.
  20. Zagashvili I. V., Yanul A. N. Some cases of NSAID-gastropathies with short-term treatment and options for their prevention. Recipe - Minsk. 2015. no. 1(99), p.104-108.
  21. Stepanov Yu. M. Drug interactions in real clinical practice. Health Ukraine. 2010, no.3, pp. 8-9.
  22. Lanza F.L., Chan F. K.L., Quigley E. M. M. Guidelines Prevention of NSAID-Related Ulcer Complications. The American Journal of Gastroenterology. 2009.vol. 104, pp.728-738.
  23. Dikareva E. A., Makarenko E. V., Pimanov S. I. Risk assessment of gastropathy induced by the use of nonsteroidal anti-inflammatory drugs, based on international consensus documents. Bulletin of VSMU. 2015. vol. 14, no. 5, pp.39-45.
  24. Levenstein S. Peptic ulcer at the end of the 20th century: biological and psychological risk factors. Can. J. Gastroenterol. 1999. vol. 68, no. 13, pp. 753-759.
  25. Petrushin A. L. Perforated gastroduodenal ulcers in children. In the book. Fedotova EV, Chakhvadze B. Yu., Petrushin A. L., Prilutsky O. V. Non-standard situations in surgery. - Stavropol: “Center for Scientific Knowledge”Logos”, 2018.
  26. Argunova I. A. Problems in establishing clinical diagnosis and management of medical reporting on ICD-10 for gastroduodenal ulcers and NSAID gastropathies. Russian journal of gastroenterology, hepatology, coloproctology. 2010, vol.20, no. 5, pp. 69-74.
  27. Durleshter V. M., Korochanskaya N. V., Serikova S. N., Didigov M. T. Algorithm of diagnosis and indications for surgical treatment of patients with gastric ulcer. Bulletin of surgical gastroenterology. 2013, no.02, pp.4-11.
  28. Lobanov V. M. Peptic ulcer: decision-making methodology. Problems of health and ecology. 2005, no. 3 (5), pp.138-143.
  29. Kosenko P. M., Vavrinchuk S. A., Sunozova GD Indicators of intragastral daily pH monitoring in patients with ulcerative pyloroduodenal stenosis. Far Eastern Medical Journal of Surgery. 2017, no. 1, p.27-30.
  30. Pantsyrev Yu.M., Chernyakevich S. A., Mikhalev A. I. Surgical treatment of ulcerative pyloroduodenal stenosis. Surgery. 2003. no 2, pp. 34-37
  31. Kodirov F. D., Kadyrov D. M., Amonov U. M., Kurbonov D. M., Kosimov Kh. Sh. Electrophysiological determination of the criteria for the reversibility of decompensation of gastric motility in ulcerative stenosis. Materials of the XXI United Russian Gastrowedeli. 2015, vol. XXV, no. 5, adj. 46, p.22

Full text is published :
Spivakovskiy Yu. M., Spivakovsky A. Yu., Chernenkov Yu. V., Volkova O. V., Goremykina I. V., Dushanova A. K. The case of atypical course of gastric ulcer in pediatric practice. Experimental and Clinical Gastroenterology. 2019;171(11): 93–99. (In Russ.) DOI: 10.31146/1682-8658-ecg-171-11-93-99
Read & Download full text

1. St. Petersburg State Pediatric Medical University of the Ministry of Health of the Russian Federation
2. Pirogov Russian National Research Medical Universityof the Ministry of Health of the Russian Federation
3. Volga Research Medical University of the Ministry of Health of the Russian Federation.
4. Morozov Children’s City Clinical Hospital, Moscow
5. Russian Medical Academy of Continuing Professional Education, Ministry of Health of the Russian Federation

Keywords: Crohn’s disease in children, draft recommendations for diagnosis and treatment, clinical recommendations

Abstract: The final version of the draft protocol for the diagnosis and treatment of Crohn’s disease in children, developed by experts of the Russian Society of Pediatric Gastroenterology, Hepatology and Nutrition, is presented in the article. This project has been repeatedly discussed by pediatric gastroenterologists - specialists in the study of IBD in children during round tables at the XXV-th and XXVI-th Congres of Pediatric Gastroenterologists of Russia and, after final approval, will be presented in the form of clinical recommendations.

• References total 236 ⇓ :: .
  1. Benchimol EI, Fortinsky KJ, Gozdyra P, Vanden-Heuvel M, VanLimbergen J, Griffiths AM. Epidemiologyofpediatricinflammatoryboweldisease: asystematicreviewofinternationaltrends. Inflamm Bowel Dis. 2011;17(1):423-39.
  2. Ruemelle F. M. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. - J. Crohn’s Colitis, 2014, v.8, 1179-1207. doi:10.1016/j.crohns.2014.04.005.
  3. Kornienko E. A. Inflammatory bowel disease in children. M., Prima Print, 2014, 208 p.
  4. Bernstein C. WHO global guidelines on Inflammatory Bowel Disease - Guidelines for the Diagnosis and Management of IBD in 2010. Inflamm Bowel Dis. 2010 Jan; 16:112-124. doi:10.1002/ibd.21048.
  5. Van Limbergen J, Russell RK, Drummond HE, Aldhous MC, RoundNK, Nimmo ER. Definition of phenotypic characteristics ofchildhood-onset inflammatory bowel disease. Gastroenterology2008; 135(4):1114-22.
  6. Vernier-Massouille G, Balde M, Salleron J, Turck D, Dupas JL, Mouterde O. Natural history of pediatric Crohn's disease: apopulation-based cohort study. Gastroenterology 2008; 135(4):1106-13.
  7. Pigneur B, Seksik P, Viola S, Viala J, Beaugerie L, Girardet JP, et al. Natural history of Crohn's disease: comparison betweenchildhood- and adult-onset disease. Inflamm Bowel Dis2010; 16(6):953-61.
  8. Ivashkin V.T. et al. Clinical recommendations of the Russian Gastroenterological Association and the Association of Coloproctologists of Russia on the diagnosis and treatment of Crohn's disease. Coloproctology. 2017, No. 2 (60), pp. 7-29.
  9. Maloy K. J., Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease - Nature insight, 2011, v.474, No7351, p.298-306
  10. Franke A. Genome-wide meta-analysis increases to 71 the number of confermed Crohn’s disease susceptibility loci - Nature genet., 2010, v.42, p.1118-1125.
  11. Strober W., Fuss I., Mannon P. The fundamental basis of inflammatory bowel disease - J. Clin. Investigation, 2007, v.117 (3), p.514-521.
  12. Langholz E., Munkholm P., Krasilnikoff P. A. Inflammatory bowel disease with onset in childhood. Clinical features, morbidity and mortality in a regional cohort. - Scand.J. Gastroenterol., 1997, v.32, p.139-147.
  13. Horsthuis K., Bipat S., Bennink R. J., Stoker J. Inflammatory bowel disease diagnosed with US, MR, scintigraphy, and CT: metaanalysis of prospective studies. Radiology. - 2008;247(1):64-79.
  14. Chashkova E.Yu., Vladimirova A.A., Neustroev V.G. Inflammatory diseases of the colon - diagnostic aspects. Bulletin of the East Siberian Scientific Center SB RAMS. 2011, No. 4-2, pp. 209-221.
  15. Lennard-Jones J. E. Classification of inflammatory bowel disease. Scand. J. Gastroenterol. Suppl. - 1989; 170:2-6.
  16. Levine A., Koletzko S., Turner D. ESPGHAN revised Porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents - J. Pediatric Gasroenterol Nutr., 2014, v.58 (6), p.795-806.
  17. Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapyfor induction of remission in Crohn's disease. Cochrane DatabaseSyst Rev 2007; 1: Cd000542.
  18. Heuschkel R. B., Menache C. C., Megerian J. T., Baird A. E. Enteralnutrition and corticosteroids in the treatment of acute Crohn'sdisease in children. J Pediatr Gastroenterol Nutr 2000;31(1):8-15.
  19. Dziechciarz P., Horvath A., Shamir R., Szajewska H. Meta-analysis: enteral nutritionin active Crohn's disease in children. Aliment Pharmacol Ther 2007;26(6):795-806.
  20. Thomas A. G., Taylor F., Miller V. Dietary intake and nutritionaltreatment in childhood Crohn's disease. J Pediatr Gastroenterol Nutr 1993; 17(1):75-81.
  21. Sanderson I. R., Udeen S., Davies P. S., Savage M. O., Walker-Smith J. A. Remission induced by an elemental diet in small bowelCrohn's disease. Arch Dis Child 1987;62(2):123-7.
  22. Seidman E., Lohoues M. J., Turgeon J., Bouthillier L., Morin C. L. Elemental dietversus prednison easinitial therapy in Crohn's disease: early and longterm results. Gastroenterology1991;100: A250.
  23. Terrin G. C.R., Ambrosini A. A semielemental diet (Pregomin) aspri- mary therapy for inducing remission in children with activeCrohn’'s disease. Ital J Pediatr 2002;28:401-5.
  24. Seidman E. G.A., Jones A., Issenman R. Semi-elemental (S-E) dietversus prednisone in pediatric Crohn's disease. Gastroenterology 1993. Gastroenterology 1993;104: A778.
  25. Ruuska T., Savilahti E., Maki M., Ormala T., Visakorpi J. K. Exclusivewhole protein enteral diet versus prednisolone in the treatmentof acute Crohn's disease in children. J Pediatr GastroenterolNutr 1994;19(2):175-80.
  26. Grogan J. L., Casson D. H., Terry A., Burdge G. C., El-Matary W., Dalzell A. M. Enteral feeding therapy for newly diagnosedpediatric Crohn's disease: a double-blind randomized controlled trial with two years follow-up. Inflamm Bowel Dis2012;18(2):246-53.
  27. Akobeng A. K., Miller V., Stanton J., Elbadri A. M., Thomas A. G. Double-blind randomized controlled trial of glutamine-enrichedpolymeric diet in the treatment of active Crohn's disease. JPediatr Gastroenterol Nutr 2000;30(1):78-84.
  28. Ludvigsson J. F., Krantz M., Bodin L., Stenhammar L., Lindquist B. Elemental versus polymericenteral nutrition in paediatric Crohn's disease: a multicentre randomized controlled trial. ActaPaediatr 2004;93(3):327-35 [Oslo, Norway: 1992].
  29. Rodrigues A. F., Johnson T., Davies P., Murphy M. S. Does polymeric formula improve adherence to liquid diet therapyin children with active Crohn's disease? Arch Dis Child2007;92(9):767-70.
  30. Critch J., Day A. S., Otley A., King-Moore C., Teitelbaum J. E., Shashidhar H. Use of enteral nutrition for the control of intestinalinflammation in pediatric Crohn disease. J Pediatr GastroenterolNutr 2012; 54(2):298-305.
  31. Whitten K. E., Rogers P., Ooi C. Y., Day A. S. International survey ofenteral nutrition protocols used in children with Crohn's disease. J Dig Dis 2012; 13 (2):107-12.
  32. Knight C., El-Matary W., Spray C., Sandhu B. K. Long-termoutcome of nutritional therapy in paediatric Crohn's disease.Clin Nutr 2005;24(5):775-9.
  33. Day A. S., Whitten K. E., Lemberg D. A., Clarkson C., Vitug-Sales M., Jackson R. Exclusive enteral feeding as primary therapyfor Crohn's disease in Australian children and adolescents: afeasible and effective approach. J Gastroenterol Hepatol 2006; 21 (10):1609-14.
  34. Berni Canani R., Terrin G., Borrelli O., Romano M. T., Manguso F., Coruzzo A. Short- and long-term therapeutic efficacy ofnutritional therapy and corticosteroids in paediatric Crohn'sdisease. Dig Liver Dis 2006;38(6):381-7.
  35. Beattie R. M., Schiffrin E. J., Donnet-Hughes A., Huggett A. C., Domizio P., MacDonald T.T. Polymeric nutrition as theprimary therapy in children with small bowel Crohn's disease.Aliment Pharmacol Ther 1994;8(6):609-15.
  36. Borrelli O., Cordischi L., Cirulli M., Paganelli M., Labalestra V., Uccini S. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol 2006;4(6):744-53.
  37. Ford A. C., Bernstein C. N., Khan K. J., Abreu M. T., Marshall.J.K., Talley.N.J. Glucocorticosteroid therapy in inflammatory boweldisease: systematic review and meta-analysis. Am J Gastroenterol2011;106(4):590-9 [quiz 600].
  38. Escher J. C. Budesonide versus prednisolone for the treatment ofactive Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial. Eur J Gastroenterol Hepatol 2004;16(1):47-54.v Levine A., Weizman Z., Broide E., Shamir R., Shaoul R., Pacht A. A comparison of budesonide and prednisone for thetreatment of active pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2003;36(2):248-52.
  39. Markowitz J., Grancher K., Kohn N., Lesser M., Daum F. Amulticenter trial of 6-mercaptopurine and prednisone inchildren with newly diagnosed Crohn's disease. Gastroenterology 2000; 119(4):895-902.
  40. Tung J., Loftus Jr. E.V., Freese.D.K., El-Youssef.M, ZinsmeisterA R., Melton III L.J. A population-based study of the frequencyof corticosteroid resistance and dependence in pediatricpatients with Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 2006;12(12):1093-100.
  41. Byron M. A., Jackson J., Ansell B. M. Effect of different corticosteroid regimens on hypothalamic-pituitary-adrenal axis and growth in juvenile chronic arthritis. J R Soc Med 1983;76(6):452-7.
  42. Modigliani R., Mary J. Y., Simon J. F., Cortot A., Soule J. C., Gendre J. P. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990;98(4):811-8.
  43. Mantzaris G. J., Christidou A., Sfakianakis M., Roussos A., Koilakou S., Petraki K. Azathioprine is superior to budesonide inachieving and maintaining mucosal healing and histologicremission in steroid-dependent Crohn's disease. Inflamm Bowel Dis 2009;15(3):375-82.
  44. Jakobsen C., Munkholm P., Paerregaard A., Wewer V. Steroiddependency and pediatric inflammatory bowel disease in theera of immunomodulators - a population-based study. InflammBowel Dis 2011; 17(8):1731-40.
  45. Levine A., Kori M., Dinari G., Broide E., Shaoul R., Yerushalmi B. Comparison of two dosing methods for induction ofresponse and remission with oral budesonide in active pediatricCrohn's disease: a randomized placebo-controlled trial. Inflamm Bowel Dis 2009; 15(7):1055-61.
  46. Dilger K., Alberer M., Busch A., Enninger A., Behrens R., Koletzko S. Pharmacokinetics and pharmacodynamic action ofbudesonide in children with Crohn's disease. Aliment Pharmacol Ther 2006;23(3):387-96.
  47. Huscher D., Thiele K., Gromnica-Ihle E., Hein G., Demary W., Dreher R. Dose-related patterns of glucocorticoid-induced sideeffects. Ann Rheum Dis 2009;68(7):1119-24.
  48. Khan K. J., Ullman T. A., Ford A. C., Abreu M. T., Abadir A., Marshall J. K. Antibiotic therapy in inflammatory bowel disease: asystematic review and meta-analysis. Am J Gastroenterol 2011;106(4):661-73.
  49. Bermejo F, Garrido E, Chaparro M, Gordillo J, Manosa M, Algaba A. Efficacy of different therapeutic options forspontaneous abdominal abscesses in Crohn's disease: areantibiotics enough? Inflamm Bowel Dis 2012; 18(8):1509-14.
  50. Levine A, Turner D. Combined azithromycin and metronidazoletherapy is effective in inducing remission in pediatric Crohn'sdisease. J Crohns Colitis 2011;5(3):222-6.
  51. Barabino A, Torrente F, Ventura A, Cucchiara S, Castro M, Barbera C. Azathioprine in paediatric inflammatory boweldisease: an Italian multicentre survey. Aliment PharmacolTher 2002;16(6):1125-30.
  52. Jaspers GJ, Verkade HJ, Escher JC, de Ridder L, Taminiau JA,.Rings EH. Azathioprine maintains first remission in newly diagnosed pediatric Crohn's disease. Inflamm Bowel Dis2006;12(9):831-6.
  53. Ramadas AV, Gunesh S, Thomas GA, Williams GT, Hawthorne AB. Natural history of Crohn's disease in a population-basedcohort from Cardiff (1986-2003): a study of changesin medical treatment and surgical resection rates. Gut2010;59(9):1200-6.
  54. Peyrin-Biroulet L, Oussalah A, Williet N, Pillot C, Bresler L, Bigard MA. Impact of azathioprine and tumour necrosis factorantagonists on the need for surgery in newly diagnosed Crohn'sdisease. Gut 2011;60(7):930-6.
  55. Cosnes J, Bourrier A, Laharie D, Nahon S, Bouhnik Y, Carbonnel F. Early administration of azathioprine vs conventionalmanagement of Crohn's Disease: a randomized controlled trial.Gastroenterology 2013;145(4):758-65 [e2; quize 14-5].
  56. Panes J, Lopez-Sanroman A, Bermejo F, Garcia-Sanchez V, Esteve M, Torres Y. Early azathioprine therapy is no moreeffective than placebo for newly diagnosed Crohn's disease.Gastroenterology 2013;145(4):766-74 [e1].
  57. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362(15):1383-95.
  58. Fuentes D, Torrente F, Keady S, Thirrupathy K, Thomson MA, Walker-Smith JA. High-dose azathioprine in childrenwith inflammatory bowel disease. Aliment Pharmacol Ther2003;17(7):913-21.
  59. Gearry RB, Barclay ML, Burt MJ, Collett JA, Chapman BA. Thiopurine drug adverse effects in a population of New Zealandpatients with inflammatory bowel disease. PharmacoepidemiolDrug Saf 2004; 13(8):563-7.
  60. Hindorf U, Lindqvist M, Hildebrand H, Fagerberg U, Almer S. Adverse events leading to modification of therapy in a largecohort of patients with inflammatory bowel disease. AlimentPharmacol Ther 2006;24(2):331-42.
  61. Kirschner BS. Safety of azathioprine and 6-mercaptopurine inpediatric patients with inflammatory bowel disease. Gastroenterology 1998; 115(4):813-21.
  62. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, DiamondRH, Price S. Serious infection and mortality in patientswith Crohn's disease: more than 5 years of follow-up in theTREAT registry. Am J Gastroenterol 2012;107(9):1409-22.
  63. Baldassano R, Colletti RB, Cucchiara S, Dubinsky M, Escher JC, Faubion WA. 41 serious infections and associated risk factors in patients receiving infliximab and immunotherapies for children with inflammatory bowel disease: develop registry data. Gastroenterology 2013;144(5 Suppl 1): S-11.
  64. Ledder OD, Lemberg DA, Ooi CY, Day AS. Are thiopurinesalways contraindicated after thiopurine-induced pancreatitisin inflammatory bowel disease? J Pediatr Gastroenterol Nutr2013;57(5):583-6.
  65. Dubinsky MC, Yangf H, Hassard PV, Seidmanll EG, Kam LY, Abreu MT. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients within flammatory bowel disease. Gastroenterology 2002; 122(4):904-15.
  66. Ansari A, Hassan C, Duley J, Marinaki A, Shobowale-Bakre EM, Seed P, et al. Thiopurine methyltransferase activity and theuse of azathioprine in inflammatory bowel disease. AlimentPharmacol Ther 2002;16(10):1743-50.
  67. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel diseasepatients treated with azathioprine and 6-mercaptopurine. Gut2005; 54(8):1121-5.
  68. Camus M, Seksik P, Bourrier A, Nion-Larmurier I, Sokol H, Baumer P, et al. Long-term outcome of patients with Crohn'sdisease who respond to azathioprine. Clin GastroenterolHepatol 2013; 11 (4):389-94.
  69. Ashworth LA, Billett A, Mitchell P, Nuti F, Siegel C, Bousvaros A. Lymphoma risk in children and young adults with inflammatory bowel disease: analysis of a large single-center cohort.Inflamm Bowel Dis 2012;18(5):838-43.
  70. Colletti RB, Cucchiara S, Dubinsky M, Escher JC, Faubion WA, Fell J. 833 malignancies in children receiving infliximab and other inflammatory bowel disease therapies: aninflammatory bowel disease multicenter, prospective, long-term registry of pediatric patients (develop) registry data. Gastroenterology 2013;144(5, Supplement 1): P-147.
  71. Kotlyar DS, Osterman MT, Diamond RH, Porter D, Blonski WC, Wasik M. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011;9(1): e1-e41.
  72. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, Bouvier AM, Chevaux JB, Simon T. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011; 141 (5):1621-8 [e1-5].
  73. Singh H, Nugent Z, Demers AA, Bernstein CN. Increased riskof nonmelanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology 2011; 141 (5):1612-20.
  74. van Schaik FD, van Oijen MG, Smeets HM, Vander Heijden GJ, Siersema PD, Oldenburg B. Thiopurines prevent advanced colorectalneoplasia in patients with inflammatory bowel disease. Gut 2012;61(2):235-40.
  75. Turner D, Grossman AB, Rosh J, Kugathasan S, Gilman AR, Baldassano R. Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn's disease. Am JGastroenterol 2007;102(12):2804-12 [quiz 3, 13].
  76. Uhlen S, Belbouab R, Narebski K, Goulet O, Schmitz J, Cezard JP, et al. Efficacy of methotrexate in pediatric Crohn's disease: a French multicenter study. Inflamm Bowel Dis 2006; 12(11):1053-7.
  77. Boyle B, Mackner L, Ross C, Moses J, Kumar S, Crandall W. Asingle-center experience with methotrexate after thiopurinetherapy in pediatric Crohn disease. J Pediatr GastroenterolNutr 2010;51(6):714-7.
  78. Mack DR, Young R, Kaufman SS, Ramey L, Vanderhoof JA. Methotrexate in patients with Crohn's disease after6-mercaptopurine. J Pediatr 1998;132(5):830-5.
  79. Ravikumara M, Hinsberger A, Spray CH. Role of methotrexatein the management of Crohn disease. J Pediatr GastroenterolNutr 2007;44(4):427-30.
  80. Weiss B, Lerner A, Shapiro R, Broide E, Levine A, Fradkin A, et al. Methotrexate treatment in pediatric Crohn diseasepatients intolerant or resistant to purine analogues. J PediatrGastroenterol Nutr 2009;48(5):526-30.
  81. Willot S, Noble A, Deslandres C. Methotrexate in the treatmentof inflammatory bowel disease: an 8-year retrospectivestudy in a Canadian pediatric IBD center. Inflamm Bowel Dis2011;17(12):2521-6.
  82. Laharie D, Reffet A, Belleannee G, Chabrun E, Subtil C, Razaire S. Mucosal healing with methotrexate in Crohn's disease: a prospective comparative study with azathioprine and infliximab. Aliment Pharmacol Ther 2011;33(6):714-21.
  83. Hashkes PJ, Becker ML, Cabral DA, Laxer RM, Paller AS, Rabinovich CE. Methotrexate: new uses for an old drug. JPediatr 2014;164:231-6.
  84. Kempinska A, Benchimol EI, Mack A, Barkey J, Boland M, Mack DR. Short-course ondansetron for the prevention ofmethotrexate-induced nausea in children with Crohn disease.J Pediatr Gastroenterol Nutr 2011;53(4):389-93.
  85. Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, et al. Induction and maintenance infliximab therapy for thetreatment of moderate-to-severe Crohn's disease in children.Gastroenterology 2007;132(3):863-73 [quiz 1165-6].
  86. Kugathasan S, Werlin SL, Martinez A, Rivera MT, Heikenen JB, Binion DG. Prolonged duration of response to infliximab in earlybut not late pediatric Crohn's disease. Am J Gastroenterol2000;95(11): 3189-94.
  87. Hyams JS, Griffiths A, Markowitz J, Baldassano RN, Faubion Jr WA, Colletti RB, et al. Safety and efficacy of adalimumab formoderate to severe Crohn's disease in children. Gastroenterology 2012; 143(2):365-74 [e2].
  88. Rosh JR, Lerer T, Markowitz J, Goli SR, Mamula P, Noe JD, et al. Retrospective Evaluation of the Safety and Effect ofAdalimumab Therapy (RESEAT) in pediatric Crohn's disease.Am J Gastroenterol 2009;104(12):3042-9.
  89. Crandall W, Hyams J, Kugathasan S, Griffiths A, Zrubek J, Olson A, et al. Infliximab therapy in children with concurrentperianal Crohn disease: observations from REACH. J PediatrGastroenterol Nutr 2009;49(2):183-90.
  90. Teitelbaum JE, Saeed S, Triantafyllopoulou M, Daum F. Infliximab in pediatric Croh'n disease patients with enterovesicular fistulas. J Pediatr Gastroenterol Nutr 2007;44(2):279-82.
  91. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas inpatients with Crohn's disease. N Engl J Med 1999;340(18):1398-405.
  92. PanaccioneR, LoftusJr EV, Binion D, McHugh K, Alam S, Chen N. Efficacy and safety of adalimumab in Canadian patientswith mod erate to severe Crohn's disease: results of theAdalimumab in Canadian SubjeCts with ModErate to SevereCrohn's DiseaSe (ACCESS) trial. Can J Gastroenterol 2011;25(8):419-25.
  93. Dewint P, Hansen BE, Verhey E, Oldenburg B, Hommes DW, Pierik M. Adalimumab combined with ciprofloxacin issuperior to adalimumab monotherapy in perianal fistula closurein Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI). Gut 2014;63:292-9.
  94. Barrie A, Regueiro M. Biologic therapy in the management ofextraintestinal manifestations of inflammatory bowel disease.Inflamm Bowel Dis 2007; 13 (11):1424-9.
  95. Kugathasan S, Miranda A, Nocton J, Drolet BA, Raasch C, Binion DG. Dermatologic manifestations of Crohn disease in children: response to infliximab. J Pediatr Gastroenterol Nutr 2003;37(2):150-4.
  96. Escher JC, Stoof TJ, van Deventer SJ, van Furth AM. Successful treatment of metastatic Crohn disease with infliximab. JPediatr Gastroenterol Nutr 2002;34(4):420-3.
  97. Krishnan S, Banquet A, Newman L, Katta U, Patil A, Dozor AJ. Lung lesions in children with Crohn's disease presenting asnonresolving pneumonias and response to infliximab therapy.Pediatrics 2006;117(4):1440-3.
  98. Silbermintz A, Krishnan S, Banquet A, Markowitz J. Granulomatous pneumonitis, sclerosing cholangitis, and pancreatitis in a child with Crohn disease: response to infliximab. J PediatrGastroenterol Nutr 2006;42(3):324-6.
  99. Carpenter E, Jackson MA, Friesen CA, Scarbrough M, Roberts CC. Crohn's-associated chronic recurrent multifocal osteomyelitis responsive to infliximab. J Pediatr 2004;144(4):541-4.
  100. Kierkus J, Dadalski M, Szymanska E, Oracz G, Wegner A, Gorczewska M, et al. The impact of infliximab inductiontherapy on mucosal healing and clinical remission in Polishpediatric patients with moderate-to-severe Crohn's disease.Eur J Gastroenterol Hepatol 2012;24(5):495-500.
  101. Malik S, Ahmed SF, Wilson ML, Shah N, Loganathan S, Naik S. The effects of anti-TNF-alpha treatment with adalimumabon growth in children with Crohn's disease (CD). J Crohns Colitis2012;6(3):337-44.
  102. Ryan BM, Russel MG, Schurgers L, Wichers M, Sijbrandij J, Stockbrugger RW. Effect of antitumour necrosisfactor-alpha therapy on bone turnover in patients with activeCrohn's disease: a prospective study. Aliment Pharmacol Ther2004;20(8):851-7.
  103. Franchimont N, Putzeys V, Collette J, Vermeire S, Rutgeerts P, De Vos M. Rapid improvement of bone metabolism afterinfliximab treatment in Crohn's disease. Aliment Pharmacol Ther 2004; 20(6):607-14.
  104. Thayu M, Leonard MB, Hyams JS, Crandall WV, Kugathasan S, Otley AR. Improvement in biomarkers of bone formationduring infliximab therapy in pediatric Crohn's disease: resultsof the REACH study. Clin Gastroenterol Hepatol 2008;6(12):1378-84.
  105. Miheller P, Kiss LS, Lorinczy K, Lakatos PL. Anti-TNF troughlevels and detection of antibodies to anti-TNF in inflammatory bowel disease: are they ready for everyday clinical use? Expert Opin Biol Ther 2012;12(2):179-92.
  106. Steenholdt C, Brynskov J, Thomsen OO, Munck LK, Fallingborg J, Christensen LA. Individualised therapy is morecost-effective than dose intensification in patients withCrohn's disease who lose response to anti-TNF treatment: arandomised, controlled trial. Gut 2014;63:919-27.
  107. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med2010;362(15):1383-95.
  108. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;3 59(9317):1541-9.
  109. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R. Adalimumab for maintenance of clinicalresponse and remission in patients with Crohn's disease: theCHARM trial. Gastroenterology 2007;132(1):52-65.
  110. Armuzzi A, Pugliese D, Danese S, Rizzo G, Felice C, Marzo. Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopicremission. Inflamm Bowel Dis 2013;19(5):1065-72.
  111. Sprakes MB, Ford AC, Warren L, Greer D, Hamlin J. Efficacy, tolerability, and predictors of response to infliximab therapyfor Crohn's disease: a large single centre experience. J CrohnsColitis 2012;6(2):143-53.
  112. Cucchiara S, Escher JC, Hildebrand H, Amil-Dias J, StronatiL, Ruemmele FM. Pediatric inflammatory bowel diseases and the risk of lymphoma: should we revise our treatment strategies? JPediatr Gastroenterol Nutr 2009;48(3):257-67.
  113. Feagan BG, McDonald JW, Panaccione R, Enns RA, Bernstein CN, Ponich TP. Methotrexate in combination with infliximab is nomore effective than infliximab alone in patients with Crohn'sdisease. Gastroenterology 2014; 146:681-8.
  114. Russell RK, Wilson ML, Loganathan S, Bourke B, Kiparissi F, Mahdi G. A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease. Aliment Pharmacol Ther 2011;33(8):946-53.
  115. Kestens C, van Oijen MG, Mulder CL, van Bodegraven AA, Dijkstra G, de Jong D. Adalimumab and infliximab areequally effective for Crohn's disease in patients not previouslytreated with anti-tumor necrosis factor-alpha agents. ClinGastroenterol Hepatol 2013; 11 (7):826-31.
  116. Baert F, Noman M, Vermeire S, Van Assche G, DHG, Carbonez A. Influence of immunogenicity on the long-term efficacyof infliximab in Crohn's disease. N Engl J Med 2003;348(7):601-8.
  117. Miele E, Markowitz JE, Mamula P, Baldassano RN. Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J PediatrGastroenterol Nutr 2004;38(5):502-8.
  118. Candon S, Mosca A, Ruemmele F, Goulet O, Chatenoud L, Cezard JP. Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease. Clin Immunol 2006; 118(1):11-9.
  119. Wynands J, Belbouab R, Candon S, Talbotec C, Mougenot JF, Chatenoud L. 12-month follow-up after successful infliximab therapy in pediatric Crohn disease. J Pediatr Gastroenterol Nutr2008;46(3):293-8.
  120. Lee LY, Sanderson JD, Irving PM. Anti-infliximab antibodies in inflammatory bowel disease: prevalence, infusion reactions, immunosuppression and response, a meta-analysis. Eur J Gastroenterol Hepatol 2012;24(9):1078-85.
  121. Jacobstein DA, Markowitz JE, Kirschner BS, Ferry G, Cohen SA, Gold BD, et al. Premedication and infusion reactions withinfliximab: results from a pediatric inflammatory bowel diseaseconsortium. Inflamm Bowel Dis 2005; 11 (5):442-6.
  122. Lahdenne P, Wikstrom AM, Aalto K, Kolho KL. Prevention of acute adverse events related to infliximab infusions in pediatric patients. Arthritis Care Res 2010;62(6):785-90.
  123. Kolho KL, Ruuska T, Savilahti E. Severe adverse reactions to infliximab therapy are common in young children with inflammatory bowel disease. Acta Paediatr 2007;96(1):128-30 [Oslo, Norway: 1992].
  124. Hamalainen A, Lahdenne P, Wikstrom A, Aalto K, Kolho KL. Prevention of infusion reactions to infliximab in paediatricpatients with oral acetylsalicylic acid. Clin Exp Rheumatol 2012;30(4):590-1.
  125. Fidder H, Schnitzler F, Ferrante M, Noman M, Katsanos K, Segaert S. Long-term safety of infliximab for thetreatment of inflammatory bowel disease: a single-centrecohort study. Gut 2009;58(4):501-8.
  126. de Bie CI, Escher JC, de Ridder L. Antitumor necrosis factor treatment for pediatric inflammatory boweldisease. Inflamm Bowel Dis 2012; 18(5):985-1002.
  127. Rahier JF, Ben-Horin S, Chowers Y, Conlon C, De Munter P, D'Haens G. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009;3(2):47-91.
  128. Mackey AC, Green L, Leptak C, Avigan M. Hepatosplenic T-cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. J Pediatr Gastroenterol Nutr 2009;48(3):386-8.
  129. Cucchiara S, Escher JC, Hildebrand H, Amil-Dias J, Stronati L, Ruemmele FM. Pediatric inflammatory bowel diseases and therisk of lymphoma: should we revise our treatment strategies? JPediatr Gastroenterol Nutr 2009;48(3):257-67.
  130. Diak P, Siegel J, La Grenade L, Choi L, Lemery S, McMahon A. Tumor necrosis factor alpha blockers and malignancy inchildren: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum 2010;62(8):2517-24.
  131. Hiremath G, Duffy L, Leibowitz I. Infliximab-induced psoriasisin children with inflammatory bowel disease. J PediatrGastroenterol Nutr 2011;52(2):230-2.
  132. Katz L, Gisbert JP, Manoogian B, Lin K, Steenholdt C, Mantzaris GJ. Doubling the infliximab dose versus halving the infusion intervalsin Crohn's disease patients with loss of response. Inflamm Bowel Dis 2012; 18(11):2026-33.
  133. Vande Casteele N, Gils A, Singh S, Ohrmund L, Hauenstein S, Rutgeerts P. Antibody response to infliximab and its impacton pharmacokinetics can be transient. Am J Gastroenterol2013; 108(6):962-71.
  134. Ben-Horin S, Waterman M, Kopylov U, Yavzori M, Picard O, Fudim E. Addition of an immunomodulator to infliximabtherapy eliminates antidrug antibodies in serum and restoresclinical response of patients with inflammatory bowel disease.Clin Gastroenterol Hepatol 2013; 11 (4):444-7.
  135. Karmiris K, Paintaud G, Noman M, Magdelaine-Beuzelin C, Ferrante M, Degenne D. Influence of trough serum level sandimmunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009; 137(5):1628-40.
  136. Dignass A, Van Assche G, Lindsay JO, Lemann M, Soderholm J, Colombel JF. The second European evidence-basedconsensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010;4(1):28-62.
  137. Griffiths A, Koletzko S, Sylvester F, Marcon M, Sherman P. Slow-release 5-aminosalicylic acid therapy in children withsmall intestinal Crohn's disease. J Pediatr Gastroenterol Nutr1993; 17(2):186-92.
  138. Cezard JP, Munck A, Mouterde O, Morali A, Lenaerts C, Lachaux A. Prevention of relapse by mesalazine (Pentasa) inpediatric Crohn's disease: a multicenter, double-blind, randomized, placebo-controlled trial. Gastroenterol Clin Biol 2009;33(1Pt 1):31-40.
  139. Lourenc R, Azevedo S, Lopes AI. Surgery in Pediatric Crohn Disease: Case Series from a Single Tertiary Referral Center. GE Port J Gastroenterol. 2016; 23(4):191-196. doi:10.1016/j.jpge.2016.03.007.
  140. Gupta N, Bostrom AG, Kirschner BS, et al. Incidence of Stricturing and Penetrating Complications of Crohn’s Disease Diagnosed in Pediatric Patients. Inflamm Bowel Dis. 2010 Apr; 16(4):638-644. doi:10.1002/ibd.21099.
  141. Kim S. Surgery in Pediatric Crohn’s Disease: Indications, Timing and Post-Operative Management. Pediatr Gastroenterol Hepatol Nutr 2017 March 20(1):14-21. doi.org/10.5223/pghn.2017.20.1.14.
  142. Kammermeier J, Morris MA, Garrick V, et al. Management of Crohn’s disease. Arch Dis Child. 2016; 101:475-480. doi:10.1136/archdischild-2014-307217.
  143. de Zoeten EF, Pasternak BA, Mattei P. Diagnosis and Treatment of Perianal Crohn Disease: NASPGHAN Clinical Report and Consensus Statement. JPGN. 2013 Sep; 57:401-412. doi: 10.1097/MPG.0b013e3182a025ee.
  144. Gecse KB, Bemelman W, Kamm MA. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn’s disease. Gut. 2014; 63:1381-1392. doi:10.1136/gutjnl-2013-306709.
  145. Gionchetti P, Dignass A, Danese S. 3rd European Evidence-Based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 2: Surgical Management and Special Situations. J Crohns Colitis. 2017; 11(2):135-149. doi:10.1093/ecco-jcc/jjw169.
  146. Bemelman WA, Warusavitarne J, Sampietro GM, et al. ECCO-ESCP Consensus on Surgery for Crohn's Disease. J Crohns Colitis. 2017 May 11. doi: 10.1093/ecco-jcc/jjx061.
  147. Mazankova L.N., Vodilova O.V., Khalif I.L. Complications of Crohn's disease in children. Coloproctology. 2004, No. 3 (9), pp. 30-35.
  148. Scherbakova O. V. Practical recommendations for the surgical treatment of complicated Crohn’s disease in children. Experimental and clinical gastroenterology. 2015, Vol. 1, No. 113, pp. 78-83.
  149. Aloi M, Viola F, D’Arcangelo G, et al. Disease course and efficacy of medical therapy in stricturing paediatric Crohn’s disease. Digestive and Liver Disease. 2013;45:464-468. doi:10.1016/j.dld.2013.01.020.
  150. Baillie CT, Smith JA. Surgical strategies in paediatric inflammatory bowel disease. World J Gastroenterol. 2015 May; 21(20):6101-6116. doi:10.3748/wjg.v21.i20.6101.
  151. Diefenbach KA, Breuer CK. Pediatric inflammatory bowel disease. World J Gastroenterol. 2006 May;12(20): 3204-3212. doi:10.3748/wjg.v12.i20.3204.
  152. Korzenik J. R. Massive lower gastrointestinal hemorrhage in Crohn’s disease. Curr. Treat Options Gastroenterol. - 2000;3:211-6.
  153. Werbin N., Haddad R., Greenberg R. Free perforation in Crohn’s disease. Isr. Med. Assoc. J. - 2003;5:175-7.
  154. Joshi A, Bajwa R, Bhattacharjee N. Bowel Perforation Associated With Infliximab Use in a Pediatrics Patient. WMJ. 2016 Apr; 115(2):90-92.
  155. Papi C., Festa V., Fagnani C. Evolution of clinical behaviour in Crohn’s disease: predictive factors of penetrating complications. Dig. Liver Dis. - 2005;37:247-53.
  156. Traa MX, Orkin BA, Flores A. Toxic colitis in a 10 year old girl with Crohn’s disease. J Ped Surg Case Reports. 2013; 1:284-287. doi.org/10.1016/j.epsc.2013.08.003.
  157. Abraham BP, Mehta S, El-Serag HB. Natural History of Pediatric-onset Inflammatory Bowel Disease. J Clin Gastroenterol. 2012 Aug; 46(7):581-589. doi:10.1097/MCG.0b013e318247c32f.
  158. Bishop J, Lemberg DA, Day AS. Managing inflammatory bowel disease in adolescent patients. Adolescent Health, Medicine and Therapeutics. 2014; 5:1-13. doi:10.2147/AHMT.S37956.
  159. Hojsak I, Kolacek S, Hansen LF. Long-term outcomes after elective ileocecal resection in children with active localized Crohn's disease - a multicenter European study. J Pediatr Surg. 2015 Oct; 50(10):1630-5. doi:10.1016/j.jpedsurg.2015.03.054.
  160. Von Allmen D. Surgical management of Crohn's disease in children. Curr Treat Options Gastroenterol. 2005 Oct; 8(5):405-10.
  161. Pfefferkorn MD, Marshalleck FE, Saeed SA. NASPGHAN Clinical Report on the Evaluation and Treatment of Pediatric Patients With Internal Penetrating Crohn Disease: Intraabdominal Abscess With and Without Fistula. JPGN2013; 57:394-400. doi: 10.1097/MPG.0b013e31829ef850.
  162. Blackburn SC, Wiskin AE, Barnes C, et al. Surgery for children with Crohn’s disease: indications, complications and outcome. Arch Dis Child 2014; 99:420-426. doi:10.1136/archdischild-2013-305214.
  163. Boualit M, Salleron J, Turck D, et al. Long-term outcome after first intestinal resection in paediatric-onset Crohn's disease: A population-based study. Inflamm Bowel Dis. 2013 Jan; 19(1):7-14. doi:10.1002/ibd.23004.
  164. Rieder F, Zimmermann EM, Remzi FH, et al. Crohn’s disease complicated by strictures: a systematic review. Gut. 2013; 62:1072-1084. doi:10.1136/gutjnl-2012-304353.
  165. Barkmeier DT, Dillman JR, Al-Hawary M, et al. MR enterography-histology comparison in resected pediatric small bowel Crohn disease strictures: can imaging predict fibrosis? Pediatr Radiol. 2016 Apr;46(4):498-507. doi:10.1007/s00247-015-3506-6.
  166. Bamford R, Hay A, Kumar D. Resection Leads to Less Recurrence Than Strictureplasty in a Paediatric Population with Obstructive Crohn's Disease. Surg Res Pract. 2014; 2014:709045. doi:10.1155/2014/709045.
  167. Simillis C., Purkayastha S., Yamamoto T., et al. A meta-analysis comparing conventional end-to-end anastomosis vs. other anastomotic configurations after resection in Crohn's disease. Dis. Colon Rectum. - 2007;50(10):1674-87.
  168. Romeo E, Jasonni V, Caldaro T, et al. Strictureplasty and intestinal resection: different options in complicated pediatric-onset Crohn disease. J Pediatr Surg. 2012 May; 47(5):944-8. doi: 10.1016/j.jpedsurg.2012.01.054.
  169. Vorobev G.I., Bolikhov K.V., Vardanyan A.V. Place of laparoscopic ileostomy in the treatment of Crohn's disease of the colon (literature review). Coloproctology. 2009, N 3 (29), pp. 52-58.
  170. Vardanyan A.V., Kashnikov V.N., Bolikhov K.V., et al. Laparoscopic ileostomy for Crohn's disease. The journal Coloproctology. 2011, No 3 (37), pp. 20-23.
  171. Mahida JB, Asti L, Deans KJ, et al. Laparoscopic bowel resection for pediatric inflammatory bowel disease. J Surg Res. 2015 Nov; 199(1):130-6. doi:10.1016/j.jss.2015.04.009.
  172. Poddubny I.V., Alieva E.I., Kozlov M. Yu., Shcherbakova O.V. Laparoscopic bowel resection in children with Crohn's disease. Pediatrics Journal G.N.Speranskogo. 2015, Vol. 94, No. 6, pp. 79-81.
  173. Diamond IR, Gerstle JT, Kim PC. Outcomes after laparoscopic surgery in children with inflammatory bowel disease. Surg Endosc. 2010 Nov; 24(11):2796-802. doi:10.1007/s00464-010-1050-x.
  174. Bobanga ID, Bai S, Swanson MA. Factors influencing disease recurrence after ileocolic resection in adult and pediatric onset Crohn’s disease. Am J Surg. 2014 Oct;208(4):591-6. doi:10.1016/j.amjsurg.2014.06.008.
  175. Abdelaal K, Jaffray B. Colonic disease site and perioperative complications predict need for later intestinal interventions following intestinal resection in pediatric Crohn's disease. J Pediatr Surg. 2016 Feb;51(2):272-6. doi:10.1016/j.jpedsurg.2015.10.078.
  176. Page AE, Sashittal SG, Chatzizacharias NA. The Role of Laparoscopic Surgery in the Management of Children and Adolescents With Inflammatory Bowel Disease. Medicine. 2015 May; 94(21):874-877. doi:10.1097/MD.0000000000000874.
  177. Diederen K, de Ridder L, van Rheenen P, et al. Complications and Disease Recurrence After Primary Ileocecal Resection in Pediatric Crohn's Disease: A Multicenter Cohort Analysis. See comment in PubMed Commons belowInflamm Bowel Dis. 2017 Feb;23(2):272-282. doi:10.1097/MIB.0000000000000999.
  178. Yamamoto T., Fazio V. W., Tekkis P. P. Safety and efficacy of strictureplasty for Crohn’s disease: a systematic review and meta-analysis. Dis. Colon Rectum. - 2007;50:1968-86.
  179. Clancy C, Boland T, Deasy J, et al. A meta-analysis of percutaneous drainage versus surgery as the initial treatment of Crohn's disease-related inta-abdominal abscess. J Crohns Colitis. 2016: 202-208. doi:10.1093/ecco-jcc/jjv198.
  180. Alkhouri RH, Bahia G, Smith AC, et al. Outcome of medical management of intraabdominal abscesses in children with Crohn's disease. J Pediatr Surg. 2017 Mar; S0022-3468(17):30208-7. doi:10.1016/j.jpedsurg.2017.03.059.
  181. Dotson JL, Bashaw H, Nwomeh B, et al. Management of Intra-abdominal Abscesses in Children With Crohn’s Disease: A 12-year, Retrospective Single-center Review. Inflamm Bowel Dis. 2015 May; 21(5):1109-1114. doi:10.1097/MIB.0000000000000361.
  182. Pini-Prato A, Faticato MG, Barabino A, et al. Minimally invasive surgery for paediatric inflammatory bowel disease: Personal experience and literature review. World J Gastroenterol. 2015 Oct; 21(40):11312-11320. doi:10.3748/wjg.v21.i40.11312.
  183. Tekkis P. P., Purkayastha S., Lanitis S., et al. A comparison of segmental vs. subtotal/total colectomy for colonic Crohn’s disease: a meta-analysis. Colorectal Dis. - 2006;8:82-90.
  184. Tichansky D., Cagir B., Yoo E., et al. Strictureplasty for Crohn’s disease: meta-analysis. Dis Colon Rectum. 2000;43:911-9.
  185. Reese G. E., Purkayastha S., Tilney H. S., et al. Strictureplasty vs. resection in small bowel Crohn’s disease: an evaluation of short-term outcomes and recurrence. Colorectal Dis. - 2007;9:686-94.
  186. Yamamoto T., Allan R. N., Keighley M. R. Effect of fecal diversion alone on perianal Crohn’s disease. World J. Surg. - 2000;24:1258-62.
  187. Melton G. B., Fazio V. W., Kiran R. P., et al. Long-term outcomes with ileal pouch-anal anastomosis and Crohn’s disease: pouch retention and implications of delayed diagnosis. Ann. Surg. - 2008;248:608-16.
  188. Bergeron V., Vienne A., Sokol H., et al. Risk factors for neoplasia in inflammatory bowel disease patients with pancolitis. Am. J. Gastroenterol. - 2010 Am J Gastroenterol. 2010 Nov;105(11):2405-11.doi:10.1038/ajg.2010.248.
  189. Jess T., Loftus Jr E. V., et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology. - 2006; 130: 1039-46.
  190. de Bie CI, Paerregaard A, Kolacek S, et al. Disease phenotype at diagnosis in pediatric Crohn's disease: 5-year analyses of the EUROKIDS Registry. Inflammatory Bowel Diseases. 2013;19(2):378-85.
  191. Dietz D. W., Laureti S., Strong S. A., et al. Safety and longterm efficacy of strictureplasty in 314 patients with obstructing small bowel Crohn’s disease. J. Am. Coll. Surg. - 2001;192:330-7.
  192. Kumar A, Auron M, Aneja A, et al. Inflammatory bowel disease: perioperative pharmacological considerations. Mayo Clin Proc. 2011; 86(8):748-757. doi:10.4065/mcp.2011.0074.
  193. Aberra FN, Lewis JD, Hass D, et al. Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology. 2003;125(2):320-7.
  194. Lake J. P., Firoozmand E., Kang J. C., et al. Effect of high-dose steroids on anastomotic complications after proctocolectomy with ileal pouch-anal anastomosis. J. Gastrointest. Surg. - 2004; 8: 547-51.
  195. Tay GS, Binion DG, Eastwood D, et al. Multivariate analysis suggests improved perioperative outcome in Crohn's disease patients receiving immunomodulator therapy after segmental resection and/or strictureplasty. Surgery. 2003;134(4):565-72.
  196. Subramanian V., Pollok R. C., Kang J. Y., et al. Systematic review of postoperative complications in patients with inflammatory bowel disease treated with immunomodulators. Br. J. Surg. - 2006; 93: 793-9.
  197. Pugliese D., Armuzzi A., Rizzo G. et al. Effect of anti-TNF-alpha treatment on short-term post-operative complications in patients with inflammatory bowel disease. Gut. - 2010; 59 (Suppl III): A13.
  198. Kopylov U, Ben-Horin S, Zmora O, et al. Anti-tumor necrosis factor and postoperative complications in Crohn's disease: systematic review and meta-analysis. Inflammatory Bowel Diseases. 2012;18(12):2404-13.
  199. Billioud V, Ford AC, Tedesco ED. Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: A meta-analysis. J Crohns Colitis. 2013;7:853-867. doi:10.1016/j.crohns.2013.01.014.
  200. El-Hussuna A, Krag A, Olaison G, et al. The effect of anti-tumor necrosis factor alpha agents on postoperative anastomotic complications in Crohn's disease: a systematic review. Diseases of the Colon & Rectum. 2013;56(12):1423-33.
  201. Yang ZP, Hong L, Wu Q, et al. Preoperative infliximab use and postoperative complications in Crohn's disease: a systematic review and meta-analysis. International Journal Of Surgery. 2014;12(3):224-30.
  202. Wagner IJ, Rombeau JL. Nutritional support of surgical patients with inflammatory bowel disease. Surg Clin North Am. 2011 Aug;91(4):787-803, viii. doi: 10.1016/j.suc.2011.04.013.
  203. Hartman C, Eliakim R, Shamir R. Nutritional status and nutritional therapy in inflammatory bowel diseases. World J Gastroenterol 2009 June 7; 15(21):2570-2578. doi:10.3748/wjg.15.2570.
  204. Jacobson S. Early postoperative complications in patients with Crohn's disease given and not given preoperative total parenteral nutrition. Scand J Gastroenterol. 2012;47(2):170-7.
  205. Li Y, Zuo L, Zhu W, et al. Role of exclusive enteral nutrition in the preoperative optimization of patients with Crohn's disease following immunosuppressive therapy. Medicine (Baltimore). 2015;94(5): e478.
  206. Keljo DJ, Markowitz J, Langton C, et al. Course and Treatment of Perianal Disease in Children Newly Diagnosed with Crohn’s Disease. Inflamm Bowel Dis. 2009 Mar; 15(3):383-387. doi:10.1002/ibd.20767.
  207. Vodilova O. V., Mazankova L. N., Khalif I. L. Features of the course of Crohn’s disease in childhood. Russian Journal of Gastroenterology, Hepatology, Coloproctology. - 2003. Vol. 11, No. 6, pp. 69-73.
  208. Rosen MJ, Moulton DE, Koyama T, et al. Endoscopic Ultrasound to Guide the Combined Medical and Surgical Management of Pediatric Perianal Crohn's Disease. Inflamm Bowel Dis. 2010 Mar; 16(3):461-468. doi:10.1002/ibd.21067.
  209. Hukkinen M, Pakarinen MP, Piekkala M et al. Treatment of complex perianal fistulas with seton and infliximab in adolescents with Crohn's disease. J Crohns Colitis. 2014; 8:756-762. doi:10.1016/j.crohns.2014.01.001.
  210. Seemann NM, Elkadri A, Walters TD, Langer JC. The role of surgery for children with perianal Crohn's disease. J Pediatr Surg. 2015 Jan; 50(1):140-3. doi:10.1016/j.jpedsurg.2014.10.034.
  211. Shelygin Yu.A., Kashnikov V.N., Bolikhov K.V. et al. The effectiveness of ileostomy in Crohn’s disease of the colon with perianal lesions. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2011, Vol. 21, No. 6, pp. 64-68.
  212. Scherbakova O. V., Ionov A. L. Comprehensive treatment of children with perianal complications of Crohn's disease. Russian Bulletin of Pediatric Surgery, Anesthesiology and Intensive Care. 2013, Vol. III, No. 4, pp. 84-91.
  213. Short SS, Dubinsky MC, Rabizadeh S, et al. Distinct phenotypes of children with perianal perforating Crohn’s disease. J Pediatr Surg. 2013 Jun; 48(6):1301-1305. doi:10.1016/j.jpedsurg.2013.03.027.
  214. Singer AAM, Gadepalli SK, Eder SJ, et al. Fistulizing Crohn’s Disease Presenting After Surgery on a Perianal Lesion. PEDIATRICS2016 Mar; 137(3): e2 0152878. DOI: 10.1542/peds.2015-2878.
  215. Shcherbakova O. V., Vrublevsky S. G., Ionov A. L., et al. Modern approaches to the treatment of pararectal fistula in children. Coloproctology. 2016, No. 2 (56) (app), pp. 51-52.
  216. Lovasz BD, Lakatos L, Horvath A, et al. Evolution of disease phenotype in adult and pediatric onset Crohn’s disease in a population-based cohort. World J Gastroenterol. 2013 Apr; 19(14):2217-2226. doi:10.3748/wjg.v19.i14.2217.
  217. Al-Breiki S, Al-Faraidy N. A Crohn’s disease rectovaginal fistula in a nine year old girl masquerading as a case of sexual abuse, and literature review. Journal of the Saudi Society of Dermatology & Dermatologic Surgery. 2013;17:25-28. doi:10.1016/j.jssdds.2012.12.001.
  218. Shelygin Yu.A., Kashnikov V.N., Bolikhov K.V., Vardanyan A.V. Predictors of the effectiveness of ileostomy in complicated forms of Crohn's disease of the colon. Annals of surgery. 2012, No. 3, pp. 37-42.
  219. Galandiuk S, Kimberling J, Al-MishlabT G, et al. Perianal Crohn Disease. Predictors of Need for Permanent Diversion. Ann Surg. 2005 May; 241(5):796-802. doi:10.1097/01.sla.0000161030.25860.c1.
  220. Gasparetto M, Guariso G, Visona L, et al. Clinical course and outcomes of diagnosing Inflammatory Bowel Disease in children 10 years and under: retrospective cohort study from two tertiary centres in the United Kingdom and in Italy. BMC Gastroenterology. 2016; 16:35. doi:10.1186/s12876-016-0455-y.
  221. Lawal TA, Frischer JS, Falcone RA, et al. The transanal approach with laparoscopy or laparotomy for the treatment of rectal strictures in Crohn's disease. J Laparoendosc Adv Surg Tech A. 2010 Nov; 20(9):791-5. doi:10.1089/lap.2009.0470.
  222. Tozer PJ, Burling D, Gupta A, et al. Review article: medical, surgical and radiological management of perianal Crohn’s fistulas. AlimentPharmacolTher. 2011; 33:5-22.
  223. Golovenko A. O., Khalif I. L., Golovenko O. V. Prevention of postoperative recurrence of Crohn's disease (literature review). Coloproctology. 2012, No. 4 (42), pp. 40-48.
  224. Bernell O, Lapidus A, Hellers G. Risk Factors for Surgery and Postoperative Recurrence in Crohn’s Disease. Ann Surg. 2000 Jan; 231(1):38-45.
  225. Gasparetto M, Guariso G. Highlights in Inflammatory Bowel Disease: Epidemiology and Its Natural History in the Paediatric Age. Gastroenterol Res Pract. 2013; 829040:12. doi:10.1155/2013/829040.
  226. Terdiman J. P. Prevention of postoperative recurrence in Crohn's disease. Clin. Gastroenterol. Hepatol. - 2008. 6(6): p. 616-20.
  227. Loly C., Belaiche J., Louis E. Predictors of severe Crohn's disease. Scand. J. Gastroenterol. - 2008;43:948-54.
  228. D. Eckert, S. Mensing, S. Sharma et al. Pharmacokinetics of Adalimumab in Paediatric Patients with Moderate to Severe Crohn’s Disease. ECCO 2013 P411.
  229. Matsumoto T, Motoya S, Watanabe K et al. Adalimumab Monotherapy and a Combination with Azathioprine for Crohn’s Disease: A Prospective, Randomized Trial J CrohnsColitis. 2016 Nov;10(11):1259-1266
  230. Rubio A, Pigneur B, Garnier-Lengline H, et al. The efficacy of exclusive nutritional therapy in paediatric Crohn's disease, comparing fractionated oral vs. continuous enteral feeding. Aliment Pharmacol Ther. 2011;33(12):1332-1339
  231. Fell JM, Paintin M, Arnaud-Battandier F, et al. Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn's disease. Aliment Pharmacol Ther. 2000;14(3):281-289.
  232. Afzal NA, Van Der Zaag-Loonen HJ, Arnaud-Battandier F, et al. Improvement in quality of life of children with acute Crohn's disease does not parallel mucosal healing after treatment with exclusive enteral nutrition. Aliment Pharmacol Ther. 2004;20(2):167-172.
  233. Miele E, Shamir R, Aloi M, et al. Nutrition in Pediatric Inflammatory Bowel Disease: A Position Paper on Behalf of the Porto Inflammatory Bowel Disease Group of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018;66(4):687-708.
  234. Grover Z, Muir R, Lewindon P. Exclusive enteral nutrition induces early clinical, mucosal and transmural remission in paediatric Crohn's disease. J Gastroenterol. 2014;49(4):638-645.
  235. Beattie RM, Schiffrin EJ, Donnet-Hughes A, et al. Polymeric nutrition as the primary therapy in children with small bowel Crohn's disease. Aliment Pharmacol Ther. 1994;8(6):609-615.

Full text is published :
Kornienko Elena A., Khavkin Anatoly I., Fedulova Elvira N., Volynets Galina V., Gabruskaya Tatyana V., Skvortsova Tamara A., Nikitin Artem V., Sorvacheva Tatyana N., Tsimbalova Ekaterina G., Shcherbakova Olga V. Draft recommendations of the russian society of pediatric gastroenterology, hepatology and nutrition on diagnosis and treatment of Crohn's disease in children. Experimental and Clinical Gastroenterology. 2019;171(11): 100–134. (In Russ.) DOI: 10.31146/1682-8658-ecg-171-11-100-134
Read & Download full text

1. Russian National Research Medical University N. I. Pirogov, Ministry of Health of Russia, Moscow, Russia

Keywords: ----

Abstract: ----

• References total ---- ⇓ :: .
   

Full text is published :
Kharitonova L. A. Anniversary Anatoly Zaprudnov — 80 Years. Experimental and Clinical Gastroenterology. 2019;171(11): 135–136. (In Russ.) DOI: 10.31146/1682-8658-ecg-171-11-135-136
Read & Download full text